**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 85503

**Manuscript Type:** REVIEW

**Acute pancreatitis: A review of diagnosis, severity prediction and prognosis assessment from imaging technology, scoring system and artificial intelligence**

Hu JX *et al*. AP diagnosis, severity prediction, prognosis assessment

Jian-Xiong Hu, Cheng-Fei Zhao, Shu-Ling Wang, Xiao-Yan Tu, Wei-Bin Huang, Jun-Nian Chen, Ying Xie, Cun-Rong Chen

**Jian-Xiong Hu,** Intensive Care Unit, The Affiliated Hospital of Putian University, Putian 351100, Fujian Province, China

**Cheng-Fei Zhao,** School of Pharmacy and Medical Technology, Putian University, Putian 351100, Fujian Province, China

**Cheng-Fei Zhao,** Key Laboratory of Pharmaceutical Analysis and Laboratory Medicine, Putian University, Putian 351100, Fujian Province, China

**Shu-Ling Wang, Xiao-Yan Tu, Wei-Bin Huang, Jun-Nian Chen, Cun-Rong Chen,** Department of Critical Care Medicine, Fujian Medical University Union Hospital, Fuzhou 350001, Fujian Province, China

**Ying Xie,** School of Mechanical, Electrical and Information Engineering, Putian University, Putian 351100, Fujian Province, China

**Author contributions:** Hu JX and Zhao CF wrote this paper and contributed equally to this work; Chen CR designed this paper; Wang SL and Tu XY checked and proofread this paper; Huang WB, Chen JN, and Xie Y searched related literature and information for this paper; all authors have read and approved the final manuscript.

**Supported by** Fujian Provincial Health Technology Project, No. 2020GGA079; Natural Science Foundation of Fujian Province, No. 2021J011380; and National Natural Science Foundation of China, No. 62276146.

**Corresponding author: Cun-Rong Chen, MD, PhD, Chief Physician, Doctor, Professor,** Department of Critical Care Medicine, Fujian Medical University Union Hospital, No. 29 Xinquan Road, Gulou District, Fuzhou 350001, Fujian Province, China.chcr789@139.com

**Received:** May 1, 2023

**Revised:** July 31, 2023

**Accepted:** September 14, 2023

**Published online:** October 7, 2023

**Abstract**

Acute pancreatitis (AP) is a potentially life-threatening inflammatory disease of the pancreas, with clinical management determined by the severity of the disease. Diagnosis, severity prediction, and prognosis assessment of AP typically involve the use of imaging technologies, such as computed tomography, magnetic resonance imaging, and ultrasound, and scoring systems, including Ranson, Acute Physiology and Chronic Health Evaluation II, and Bedside Index for Severity in AP scores. Computed tomography is considered the gold standard imaging modality for AP due to its high sensitivity and specificity, while magnetic resonance imaging and ultrasound can provide additional information on biliary obstruction and vascular complications. Scoring systems utilize clinical and laboratory parameters to classify AP patients into mild, moderate, or severe categories, guiding treatment decisions, such as intensive care unit admission, early enteral feeding, and antibiotic use. Despite the central role of imaging technologies and scoring systems in AP management, these methods have limitations in terms of accuracy, reproducibility, practicality and economics. Recent advancements of artificial intelligence (AI) provide new opportunities to enhance their performance by analyzing vast amounts of clinical and imaging data. AI algorithms can analyze large amounts of clinical and imaging data, identify scoring system patterns, and predict the clinical course of disease. AI-based models have shown promising results in predicting the severity and mortality of AP, but further validation and standardization are required before widespread clinical application. In addition, understanding the correlation between these three technologies will aid in developing new methods that can accurately, sensitively, and specifically be used in the diagnosis, severity prediction, and prognosis assessment of AP through complementary advantages.

**Key Words:** Acute pancreatitis; Imaging technology; Scoring system; Artificial intelligence; Severity prediction; Prognosis assessment

**©The** **Author(s) 2023.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Hu JX, Zhao CF, Wang SL, Tu XY, Huang WB, Chen JN, Xie Y, Chen CR. Acute pancreatitis: A review of diagnosis, severity prediction and prognosis assessment from imaging technology, scoring system and artificial intelligence. *World J Gastroenterol* 2023; 29(37): 5268-5291

**URL:** <https://www.wjgnet.com/1007-9327/full/v29/i37/5268.htm>

**DOI:** https://dx.doi.org/10.3748/wjg.v29.i37.5268

**Core Tip:** In this review, we comprehensively analyzed, discussed, and summarized the latest progress in the diagnosis, severity prediction, and prognosis assessment of acute pancreatitis from the aspects of imaging technologies, scoring systems, and artificial intelligence. This review provided comprehensive guidance and suggestions with clinical value for the diagnosis and treatment of acute pancreatitis.

**INTRODUCTION**

Acute pancreatitis (AP) is an inflammatory disorder resulting from intracellular activation and leakage of improper proteolytic enzymes, including active inflammation and pancreatic injury[1,2]. AP can result in nausea, vomiting, severe upper abdominal pain, abnormal release of pancreatic juice, or a systemic inflammatory response syndrome with fever, low blood pressure, and in some cases failure of one or more organs[2]. AP is one of the most common causes of hospitalization from gastrointestinal diseases, with a global incidence rate ranging from 13 to 45 cases per 100000 individuals annually[2,3]. Globally, the incidence of AP varies, with the North America and Western Pacific regions (as defined by the World Health Organization) experiencing the highest rates, surpassing 34 cases per 100000 individuals annually[4]. The incidence of AP has steadily increased over time in most countries of the Western world[5]. In the United States, the rate of AP-related hospitalization increased from 65.4 to 81.9 per 100000 adults from 2001 to 2014[6].

***Classification of AP based on severity***

AP, often worsened by comorbidities and demographic factors such as obesity, type 2 diabetes, cardiovascular and renal diseases, alcohol use disorder, and age over 45, is classified by severity into three categories: Mild AP (MAP), moderately severe AP (MSAP), and severe AP (SAP)[7]. SAP typically results in pancreatic necrosis, systematic inflammation, and multi-organ dysfunction and failure. Its mortality rate, ranging from 20%-40%, significantly surpasses those of MAP and MSAP[8]. The volume of extrapancreatic necrosis positively correlates with the complication rate of SAP, potentially serving as an indicator for predicting adverse outcomes in AP[9]. Early prediction of SAP with high mortality remains a challenge due to the limited accuracy of current predictive tools and the complex clinical features of SAP[10].

MSAP is characterized by transient organ failure, local complications, or exacerbation of comorbid disease, and SAP is defined by persistent organ failure lasting more than 48 h[11]. MSAP is linked to transient organ failure, while SAP involves persistent organ failure, often necessitating intensive care management[7]. The early identification of SAP is critical for the stratification and treatment of patients. Additionally, for SAP, it is crucial to avoid interventions that are either excessive and premature or insufficient and delayed; instead, a progressive intervention approach should be implemented at the appropriate time. The development of risk stratification tools that meet clinical needs and guide clinicians in terms of resource allocation, patient consultation and clinical audit, and the multidisciplinary approaches including evidence-based care are essential to achieve optimal clinical outcomes[12]. Therefore, early assessment of the etiology and severity of AP is essential for prompt treatment and close monitoring of severe patients.

***Pathophysiology of AP***

The pathophysiology of AP involves acinar cell damage, resulting in premature intrapancreatic activation of digestive proteases[13]. The pathological factors of AP includes calcium (Ca2+) overload, mitochondrial dysfunction, impaired autophagy, endoplasmic reticulum stress, unfolded protein response, intraductal fluid stasis, genetic mutations (*e.g.,* *PRSS1* or *CTFR* gene), unsaturated fatty acids, and exosomes, which mainly lead to inappropriate activation of trypsinogen, infiltration of inflammatory cells, and destruction of secretory cells[14,15]. Ca2+ overload is a prevalent mechanism causing cell damage in the body[15]. Intracellular Ca2+ overload and mitochondrial dysfunction, induced by cholecystokinin, excessive alcohol consumption, and bile acids, have been identified as key steps in SAP development caused by acinar cell dysfunction[15]. Mitochondrial dysfunction hinders cell autophagy, leading to increased production of reactive oxygen species and cytokines, which exacerbates pancreatic cell damage[15]. Mitochondrial injury exacerbates endoplasmic reticulum stress and lysosomal damage, promoting the release and activation of cathepsinogen and trypsinogen, which results in cytoplasmic protein degradation and cell necrosis[15].

***Uncertainty of serum amylase and lipase in diagnosing AP***

Common biochemistry markers used in clinical practice include amylase and lipase in serum, but clinicians must be aware of the difference in half-life between the two[12]. In serum, amylase returns to normal limits within 3-5 d, and lipase returns to normal limits within 8-14 d[12]. Elevated serum amylase and/or lipase levels support the clinical suspicion of AP, and the measurement of amylase is more widely used[16]. However, about 40% of serum amylase is derived from the pancreas, with the rest primarily from the salivary glands[16]. Therefore, the elevation of serum total amylase is not specific for pancreatitis, and other intra-abdominal diseases should be considered[16]. For example, Gumaste *et al*[17] reported that the sensitivity of serum amylase in detecting AP was 72% and the specificity was 99%. In a prospective study including 500 patients with acute abdominal pain, the serum amylase assay had a sensitivity of 85% (with a cutoff value of 300 U/L for the upper reference limit) and a specificity of 91%[18]. Another prospective study showed that the sensitivity and specificity of total amylase in serum were 45% and 97%, respectively, at the calculated diagnostic threshold of 175 U/L[19].

In some non-pancreatic diseases, there is also a false elevation of serum amylase. For example, Hu *et al*[20] reported a case of hyperamylasemia with an average serum amylase value of 881 U/L, significantly exceeding the reference range of 10-220 U/L. In addition, elevated levels of amylase and lipase, while indicative, are not exclusive to AP and may result from conditions such as bowel obstruction, infarction, cholecystitis, or perforated ulcer[21]. However, the sensitivity of serum lipase ranges from 85%-100%; while some studies reported it was less sensitive than serum amylase, others contended it surpassed amylase in sensitivity[22].

***Current clinical diagnosis of AP***

The definition of severity in AP is pivotal for determining the therapeutic approach. Patients with MAP typically respond to conservative treatment, while those patients with necrotizing pancreatitis often experience organic dysfunction, necessitating intensive care and regular therapeutic interventions, with a more uncertain prognosis[1]. Currently, the clinical diagnosis of AP necessitates meeting two of the following three criteria: (1) Abdominal pain consistent with AP; (2) Serum levels of amylase or lipase exceeding three times the upper normal limit; and (3) Cross-sectional abdominal imaging findings consistent with AP[23]. It is important to note that two of these criteria alone may fail to identify one-quarter of AP patients and misdiagnose it in one-tenth of patients[23].

At present, there is still no single scoring system that can cover all the issues related to the management and evaluation of AP. AP continues to be one of the most intricate digestive disorders in terms of clinical course and outcome, and its inherent variability in each case makes it both challenging and captivating[24]. Meanwhile, to predict the severity and mortality of AP, clinicians evaluate clinical data, including assessing organ function, conducting laboratory tests and imaging, and utilizing severity-of-the-disease rating systems, such as Ranson, Acute Physiology and Chronic Health Evaluation (APACHE) II, Balthazar’s computed tomography severity index (CTSI), modified Mortele’s CTSI (MCTSI), Bedside Index for Severity in AP (BISAP), harmless AP score (HAPS), and the first artificial intelligence (AI) model, EASY-APP[25]. In addition to these, the latest imaging studies and clinical scoring systems for the early diagnosis, prognosis assessment, and severity prediction of AP have been extensively studied and reported. In this review, we provided a detailed discussion and analysis of the latest imaging examinations and some scoring systems applied in this field to afford more valuable guidance to more accurately diagnose, predict, and assess AP.

**IMAGING TECHNOLOGY**

Imaging technology still plays a fundamental role in the initial evaluation, identification of severe cases, prognosis prediction, and decision-making for the treatment and management of AP patients[1]. An accurate description of imaging findings is crucial in all diseases, particularly in diseases like AP where the appropriate therapy depends on precise diagnosis[26]. The manifestations of pancreatic diseases are variable, and imaging plays an important role in the diagnosis and treatment of pancreatic diseases[27]. Imaging evaluation is still essential to validate the clinical diagnosis, ascertain the etiology, exclude other causes of pain related to elevated levels of amylase and/or lipase, and assess the severity and extent of AP[1].

Imaging modalities for the pancreas encompass plain X-ray, ultrasonography (US), endoscopic ultrasound (EUS), endoscopic retrograde cholangiopancreaticography (ERCP), computed tomography (CT), magnetic resonance imaging (MRI), and magnetic resonance cholangiopancreatography[27]. US is usually considered to be the only appropriate modality in the early phase of AP with typical presentations and is used for the detection of gallstones. CT and MRI are suitable for patients in the early phase of AP with equivocal presentation[28]. In emergency situations, CT and US are the preferred imaging modalities due to their advantages of accessibility, speed, and lower cost[29]. Early detection of CT imaging may influence the diagnosis or treatment in up to 15% of AP patients presenting to the emergency department, particularly in older patients with a history of pancreatitis and biliary interventions.

However, abdominal US may offer a more precise screening for biliary etiologies and provide a more informed direction for subsequent treatment[30]. Based on the fact that US often shows a regular pancreatic structure, the main role of transabdominal US in AP is to identify gallstones and/or choledocholithiasis, which is useful especially for the evaluation of biliary tract[31,32]. However, because of the presence and overlap of bowel gas, US is not possible to visualize pancreatic distal abnormality in the detection of AP[31,32].

In the late phase, typically 48-72 h post-presentation, CT and MRI serve as primary imaging modalities for AP patients, facilitating the assessment of etiology, complications, disease extent, interventions, and subsequent follow-up[28]. For example, as early as 2007, Stimac *et al*[33] reported that non-enhanced MRI was comparable to contrast-enhanced CT (CECT) in the early assessment of AP severity, with both methods demonstrating equal efficacy in predicting local and systemic complications of AP. MRI of the pancreas serves as both a problem-solving tool following CT or US evaluations and an initial imaging examination of choice. Furthermore, magnetic resonance cholangiopancreatography is valuable for detecting and evaluating pancreatic ductal anomalies, such as pancreas divisum and annular pancreas[34].

***Abdominal CT***

Radiological evaluation, especially by CT, plays a pivotal role in the definition of managing severe cases, particularly in characterizing local complications that impact the prognosis and dictate the therapeutic approach[1]. CT is an outstanding noninvasive diagnostic tool for discerning the origins of endocrine and exocrine pancreatic insufficiencies in most patients, and its significance has grown considerably in the diagnosis, treatment, and follow-up of AP patients[21,27,35]. CT is commonly used to assess the severity of the inflammatory process, ascertain the presence and extent of pancreatic necrosis, and identify local complications[21]. CT with high spatial resolution and rapid acquisition is the preferred for diagnosing AP and associated local complications[36]. Moreover, CT can clearly display the pancreas and adjacent tissues and is more precise than US in diagnosing and delineating the extent of pancreatic disease[36,37].

CECT plays a pivotal role in assessing the scope and progression of AP and stands as the primary imaging modality for initially pinpointing local complications. Typical cross-sectional imaging features encompass pancreatic enlargement, pancreatic edema, uneven density, peripancreatic fat stranding, and fluid collection[15,38]. For example, on CECT, SAP patients typically exhibit larger amounts of peripancreatic retroperitoneal fluid[39]. Approximately 7 d after the onset of AP, initial CECT plays a significant role in predicting infected pancreatic necrosis, which underscores the significance for clinicians to contemplate the initial imaging of the pancreas[40]. In addition, CT is regarded as the gold standard for imaging evaluation of AP due to its satisfactory effectiveness, outstanding timeliness, and widespread availability[1]. A lack of clinical response to appropriate conservative treatment within 48-72 h often indicates the necessity for a CT scan to verify the initial diagnosis, assess the severity of the onset, and identify any complications[41].

In 1990, Balthazar *et al*[42] developed CTSI by integrating observations of peripancreatic inflammation, phlegmon, and the degree of pancreatic necrosis evident in initial CT examinations. To enhance the accuracy in predicting the prognosis of AP patients, Mortele *et al*[43] simplified the assessment of fluid collections and the extent of pancreatic necrosis in CTSI and added features that reflect organ failure and extrapancreatic complications, leading to the development of MCTSI. MCTSI grading of AP was significantly associated with duration of hospitalization, requirements for intensive care unit (ICU), necessity for intervention, and organ failure[44]. CTSI is an easy-to-calculate and informative tool and is considered to be a good predictor of mortality and severity of AP[45].

A prospective study including 50 patients evaluated prognostic correlation and clinical outcome of AP using both Balthazar’s CTSI and modified Mortele’s CTSI[27]. In this study, Raghuwanshi *et al*[27] concluded that the scores derived from the modified Mortele’s CTSI exhibited a more robust correlation for all outcome parameters in all the patients compared to Balthazar’s index. They asserted that CECT served as an outstanding diagnostic tool for staging the inflammatory process, identifying pancreatic necrosis, detecting local complications, and grading the severity of AP[27]. Contrary to expectation, the 2012 Revised Atlanta Classification (RAC) demonstrated greater accuracy than the modified Mortele’s and Balthazar’s CTSI in assessing mortality and organ failure among AP patients[27].

In a study including 178 patients with interstitial edematous pancreatitis, Song *et al*[46] indicated that the initial CECT findings of peripancreatic fluid and heterogeneous enhancement in the pancreatic parenchyma could serve as useful predictors for the progression to necrotizing pancreatitis (NP) in patients initially diagnosed with interstitial edematous pancreatitis. However, it was disconcerting that the early CT scan might not conclusively diagnose NP[46]. Tasu *et al*[47] demonstrated that a pancreatic enhancement threshold of less than 30 UH on post-contrast CT images during the portal phase provided an accurate and consistent criterion for diagnosing NP. Badat *et al*[48] highlighted that using the 2012 RAC to categorize pancreatic and peripancreatic collections by CT yielded moderate interobserver agreement, underscoring the potential necessity to either devise a new semiology for characterizing peripancreatic collections by CT or to employ alternative imaging modalities like MRI for more precise analysis of collection contents.

However, the latest relevant clinical research also has encouraging results. A retrospective cross-sectional study enrolled 1924 patients experiencing their first episode of AP from three tertiary referral centers in three different prefecture-level cities of Sichuan Province in China and revealed a positive rate of 96.7% (1860/1924) for CT findings in AP diagnosis based on CECT[49]. Among these 1860 AP patients with affirmative CT results, MCTSI exhibited positive correlations with both the 2012 RAC and APACHE II, as evidenced by Spearman’s rank correlation coefficients[49].

However, there remains a puzzling contradiction, *i.e.,* CTSI and MCTSI remain inconsistent in assessing the severity and clinical outcome of AP. Bollen *et al*[50] determined that there was no notable distinction between CTSI and MCTSI in assessing AP severity. Both CT indexes were more accurate for diagnosing AP severity and had a better correlation with the need for intervention and pancreatic infection in comparison with APACHE II. Sahu *et al*[51] concluded that both CTSI and MCTSI significantly correlated with the clinical outcome of AP and aligned well with RAC grading of severity. MCTSI demonstrated higher sensitivity albeit with lower specificity than CTSI in differentiating MAP from MSAP/SAP. Alberti *et al*[52] determined that CT indexes surpassed APACHE II in assessing the severity in AP, with CTSI holding a slight advantage over MCTSI. Additionally, CTSI precisely predicted pancreatic infections and intervention requirements. Liao *et al*[53] indicated that both CTSI and MCTSI were significantly associated with clinical prognosis, offering higher accuracy in predicting infectious pancreatic necrosis but less precision in predicting persistent organ failure compared to APACHE II.

Another important factor affecting the effectiveness of CECT in assessing AP severity is the appropriate timing. Dachs *et al*[54] indicated that early abdominal CT did not offer benefits to afebrile patients experiencing their first episodes of AP. The evidence-based guidelines from the International Association of Pancreatology/American Pancreatic Association recommend that the optimal timing for an initial CT assessment should be between 72-96 h following the onset of symptoms[55]. However, until now, the appropriate point in time for when CECT should be performed to provide an accurate assessment for AP has not been well established in clinical practice. For example, in a retrospective study with 309 SAP patients, Huang *et al*[56] highlighted that the optimal timeframe for CECT evaluation of SAP-associated complications was between 72 h and 1 wk following the onset of SAP, particularly for SAP patients with infection. Their findings revealed that the severity of the disease and its alterations manifested as expanded areas of acute peripancreatic fluid collection (APFC) and increased exudation of pleural effusion within the first 1 wk of SAP onset[56]. However, the former showed a decrease after 4 wk or more, while the latter reduced after 2 wk or more[56].

Pocard and Soyer[57] found that a meticulous review of the current literature failed to offer compelling evidence regarding a specific interval between symptom onset and CT examination, suggesting that the pertinent matter of timely CT examination in AP patients remains inadequately addressed by the existing studies. In this regard, an important and outstanding issue is that the optimal time point for CECT to evaluate SAP patients’ needs to be determined by larger multicenter clinical studies to improve accuracy of disease diagnosis, avoid unnecessary CECT tests, promote early intervention, and thus improve prognosis.

***Chest CT***

In AP patients, thoracic complications encompass pleural effusion, pulmonary consolidation, atelectasis, pulmonary embolism, cardiac tamponade, pericardial effusion, elevated diaphragms, mediastinal pseudocysts, and acute respiratory distress syndrome (ARDS), the first two of which are common in AP[58-65]. In AP patients, pleural effusion accounted for 50% on admission, and the emergence of pulmonary consolidation was associated with the onset of respiratory failure[66]. A retrospective study from three Chinese Acute Pancreatitis Centers showed that 232 out of 465 AP patients had positive pleural effusion, accounting for 49.9%[67]. In a study including 358 AP patients from seven European centers, more than half of the patients had pleural effusion, with the proportion of 54.4% (195/358), and pleural effusion appeared mostly bilaterally (150/195, 76.9%)[64]. It has been reported that AP patients with bilateral pleural effusion had a significantly worse 1-year survival[64]. Bilateral pleural effusion/pulmonary consolidation was suggestive of SAP to a certain extent, and it was considered that measurement of these two parameters has certain clinical value in assessing the severity and prognosis of AP[68]. Moreover, the early onset of pleural effusion highlights its clinical significance and predicts a poor prognosis in AP[63].

In a single center study with 309 AP patients, Peng *et al*[65] explored the predictive significance of semiquantitative pleural effusion and pulmonary consolidation in determining AP severity using chest CT. In AP patients without organ failure, the values of pleural effusion and pulmonary consolidation were 25.4 ± 23.5 mL and 0.8 ± 1.0 points, respectively, which were lower than the corresponding values of 137.4 ± 116.9 mL and 2.4 ± 1.2 points observed in AP patients with organ failure[65]. Simultaneously, the values of pleural effusion and pulmonary consolidation in AP patients without death were 39.0 ± 36.0 mL and 1.0 ± 1.1 points, respectively, and were lower than the corresponding values of 144.0 ± 140.3 mL and 3.0 ± 1.1 points in the patients who died[65]. In addition, in predicting SAP, the accuracy of pleural effusion volume (mean value of 41.7 ± 38.0 mL, range of 1-1079 mL) and pulmonary consolidation score (mean value of 1.0 ± 1.2 points, range of 0-5 points) was similar to that of CTSI, APACHE II, and BISAP. For predicting organ failure, both the parameters had the same accuracy with the three scores, suggesting that the two parameters could provide prediction of SAP occurrences and organ failure in the early stage[65]. More importantly, this clinical study may increase the application value of CT due to the important role of these two parameters in predicting AP severity.

In a retrospective study from three medical centers, Yan *et al*[67] reported that the mean volume of pleural effusion was 98.8 ± 113.2 mL in 465 AP patients. The volume of pleural effusion exhibited significant and robust correlations with C-reactive protein (CRP), duration of hospital stay, and scoring systems, such as Ranson, BISAP, Marshall, APACHE II, CTSI, and extrapancreatic inflammation on CT, and displayed considerable accuracy in predicting outcomes like severity, infection, mortality, procedural needs, ICU admission, and organ failure[67]. Luiken *et al*[64] categorized the volume of pleural effusion in 195 AP patients as low (48.2%, 94/195), moderate (30.3%, 59/195), and severe (21.5%, 42/195). Their findings suggest that the presence of bilateral and/or moderate to severe amounts of pleural effusion in the early phase of AP could independently predict SAP[64].

Thus, the volume of pleural effusion can serve as a dependable radiological biomarker to predict the severity and clinical outcome of AP. In addition, larger and more multi-center prospective studies need to be conducted to promote the clinical application of pleural effusion in the prediction of AP severity. So far, there is an absence of an established quantitative grading system for pleural effusion, meriting attention in forthcoming clinical research.

***Practical problems in the application of CT in AP***

Based on advances in predicting and diagnosing AP severity, CECT is considered the diagnostic criterion for assessing AP. However, there is a non-negligible situation where contrast CT is contraindicated in patients with renal dysfunction and in pregnant women, and it is not possible to replicate follow-up studies due to cost and radiation exposure. When uncomplicated AP is diagnosed both clinically and biochemically, CT is superfluous; minimizing its overuse will not only curtail healthcare costs but also diminish radiation exposure to patients[69]. CT on admission to predict outcome does not appear to have an advantage compared with the simpler and more readily available clinical scoring systems. Therefore, CT on the day of admission to assess severity is not recommended[70]. Improvement measures aimed at curbing the overuse of early imaging in AP patients may diminish superfluous imaging, elevate quality of care, and curtail wastage[71].

In addition, CT possesses limitations in assessing the severity of AP, and it is difficult to distinguish between necrosis and local effusion in small nonenhanced areas of the pancreas[36]. Without pancreatic parenchymal necrosis, small organized peripancreatic fluid collections might be misconstrued as pseudocysts on CT, leading to an underestimation of extrapancreatic necrosis[72]. These disadvantages limit the use of CT in some situations, and there is a need to develop other methods that can be used for the diagnosis and prognosis evaluation of AP. Furthermore, it is recommended that future studies should incorporate reliable non-radiological and laboratory-based categorization tests to enhance the precision in determining and assessing the severity and prognosis of AP, thereby reducing morbidity and mortality associated with post-necrotic inflammation of the pancreas.

***MRI***

While CT remains the prevalent choice for evaluating AP, MRI has demonstrated greater sensitivity than CT in detecting AP[34]. MRI, a noninvasive technology boasting high tissue contrast and multiple acquisition sequences, effectively aids in determining the diagnosis, complications, and severity of AP[36]. When CT yields negative results but there remains a strong clinical suspicion of AP, fat-saturated turbo spin echo T2-weighted or diffusion-weighted imaging sequences can reveal nuanced pancreatic and/or peripancreatic inflammation[73]. MRI holds a pivotal role in the diagnosis of AP and is instrumental in assessing and characterizing extrapancreatic necrosis, inflammation, splenomegaly, and tissue involvement, including vascular, transverse-mesocolon, interfascial plane, and the gastrointestinal tract, in AP patients[21,74-80]. MRI can effectively capture the intra-abdominal inflammatory spread that affects mesenteric and omental fatty regions, indicative of a pathological manifestation of intra-abdominal fat edema combined with fat necrosis resulting from AP[81].

MRI is particularly beneficial for imaging of patients with iodine allergies or renal insufficiency, characterizing fluid collections and evaluating abnormalities or disconnections in the pancreatic duct[38]. As an alternate method for diagnosing AP, MRI shows great potential in clinical applications. MRI offers superior capabilities in diagnosing early extrapancreatic necrosis compared to CT, without the need for radiation, making it suitable for repeated follow-up assessments[74]. MRI more adeptly identifies the subtlest changes in AP and can delineate the constituents of mild extrapancreatic inflammatory effusions that might be missed on CT[82]. Fat-saturated T2-weighted MRI offers superior sensitivity in detecting fluid and no liquefied material in extrapancreatic collections compared to CT, while T1-weighted MRI is beneficial for identifying pancreatic or peripancreatic hemorrhage[74].

***MRI in hemorrhage, tissue necrosis, and APFC***

Compared to CT, MRI demonstrates superior sensitivity in visualizing hemorrhages, which appear hyperintense on T1-weighted imaging during the acute phase and maintain their signal intensity longer than on CT[36]. In necrotizing pancreatitis, MRI offers superior soft tissue contrast compared to CT and excels in visualizing hemorrhage and tissue necrosis[36]. A retrospective study including 539 AP patients demonstrated that MRI was superior in detecting hemorrhage associated with AP compared to CT, even when CT showed no signs of hemorrhage[83]. This study revealed that pancreatitis in AP patients with accompanying hemorrhage presented with greater clinical severity, increased susceptibility to organ failure, and prolonged hospital stays, suggesting that early hemorrhage detection on MRI could serve as a novel severity indicator in AP associated with poorer prognosis[83]. Additionally, due to its enhanced tissue resolution, MRI is poised as the frontline imaging technology for evaluating AP and its complications, notably the identification of hemorrhage[83].

In a retrospective analysis including 301 AP patients, MRI revealed that 24.9% exhibited at least one peripancreatic vascular abnormality related to AP, and the incidence of peripancreatic vascular involvement was notably more pronounced in necrotizing pancreatitis compared to edematous pancreatitis[76]. The common manifestations of early AP on MRI were splenic vein phlebitis and splenic artery involvement/arteritis, and 6.3% of the patients had splenic artery arteritis complicated with hemorrhage in the early phase of AP[76]. The findings highlighted the efficacy of MRI in delineating the progression of inflammatory processes and associated vascular changes during treatment, and early-stage vascular involvement detected by MRI might serve as a valuable indicator of AP severity[76].

Since the introduction of abdominal US and CT in the early 1970s, there has been a marked increase in the identification of acute fluid collections in AP, accompanied by a deeper insight into their natural progression and management[84]. APFC can complicate acute interstitial edematous pancreatitis, manifesting in approximately 30%-50% of such cases[85]. If APFC was associated with high BISAP (≥ 3) and CRP levels (≥ 150 mg/L) after 48 h from admission or with persistent clinical symptoms reflecting prolonged inflammatory responses, SAP patients with APFC were more likely to develop late complications[86]. Acute necrotic collections, observed exclusively in necrotic pancreatitis within the first 4 wk of onset, comprise varying amounts of fluid and necrosis, with the latter potentially affecting the pancreatic parenchyma or peripancreatic tissues, or both[36]. Pancreatic necrosis, characterized by focal, multifocal, or diffuse devitalized tissue within the pancreas, either superficial or deep, is deemed a critical imaging indicator of necrotizing pancreatitis[81]. A significant correlation exists between the presence of pancreatic necrosis and extrapancreatic fluid collections in relation to the clinical parameters, with an increase in extrapancreatic fluid collections aligning with the escalating severity of AP[87].

While CT has emerged as the primary noninvasive tool for identifying local complications in AP, it is difficult to distinguish between APFC and acute necrotic collection in the early phase due to its limited sensitivity in revealing the necrosis debris of peripancreatic tissue[81]. Given its exceptional resolution for soft tissues, MRI surpasses CT in delineating pancreatic/peripancreatic fluid collections, especially in quantifying solid debris and fat necrosis, serving as an alternative in cases with CT contraindications[88]. In MRI findings, hemorrhage in the pancreas and/or surrounding tissues may intermingle with necrosis of these same regions, manifesting as spotted, patchy, or extensive regions of hyperintensity on T1-weighted fat-suppressed images[81]. In a retrospective study including 70 AP patients, Zhou *et al*[74] discovered that MRI characteristics of extrapancreatic collections, particularly its extent and amount, could differentiate early extrapancreatic necrosis from peripancreatic fluid collections, suggesting the presence of extrapancreatic necrosis. Moreover, the more extensive the extrapancreatic collections and the broader the scope of extrapancreatic inflammation associated with hemorrhage in AP on MRI, the higher the likelihood of extrapancreatic necrosis[74].

In a meta-analysis encompassing a total of 566 patients, MRI demonstrated superior accuracy and sensitivity compared to CT for diagnosing AP[89]. While no study has yet shown that MRI can decrease AP mortality or enhance prognosis, MRI serves as an invaluable diagnostic tool for distinguishing individuals with suspected AP and is regarded as the premier imaging choice for the clinical diagnosis of AP[89]. Tang *et al*[82], utilizing MRI and APACHE II, devised a novel model through logistic regression for the early prediction of AP severity and ascertained that the combined model of extrapancreatic inflammation on MRI (EPIM) and APACHE II excelled in predicting AP severity, surpassing individual parameters. This retrospective analysis including 363 AP patients suggested that merging MRI and APACHE II for gauging AP severity was both viable and more accurate than other scoring mechanisms, potentially facilitating the creation of tailored treatment and management[82].

***MRI severity index in AP***

MRI severity index (MRSI), derived from CTSI, evaluates the severity of AP by integrating both peripancreatic inflammation and pancreatic parenchymal necrosis, achieving an effect comparable to that of CTSI in assessing AP severity[36]. In patients with pancreatitis, MRSI outperformed APACHE II in assessing local complications, while APACHE II demonstrated superiority in determining systemic complications[90]. MRSI is pivotal for the initial assessment, staging, and prognosis of AP. The clinical relevance of MRSI allows for prediction of the severity of AP based on initial MRI findings in the early phase, and it holds a significant correlation with APACHE II, incidence of systemic complication, duration of hospital stay, and overall clinical outcome[81]. In a retrospective study including 337 AP patients, Zhou *et al*[75] reported that in the early stages of AP EPIM based on MRI proved more effective in assessing the severity than extrapancreatic inflammation on CT . Moreover, the predictive accuracies of EPIM for SAP and organ failure aligned with those of APACHE II and BISAP, surpassing the accuracy of MRSI[75].

Overall, MRI serves as an excellent instrument for identifying and distinguishing prevalent local complications subsequent to AP. MRI offers diagnostic and prognostic value on par with CT, though it presents certain limitations in clinical practice. The scans necessitate greater cooperation of the patient, including prolonged immobility and apnea, and are more time-consuming and costly[1]. Additionally, MRI has the limitation of a restricted field of view, preventing it from capturing extensive regions of the chest and pelvic cavity simultaneously, as CT can[81].

***US***

Based on its quick, simple, repeatable, radiation-free, bedside applicability, US is the first-line imaging method in most medical centers to confirm the diagnosis of AP and exclude other causes of acute abdomen. In the early period, the advantages of US are its capability of assessing the gallbladder and biliary tract, detecting gallstones, and identifying bile duct dilatation[21]. However, US may show normal pancreas in MAP patients and is not able to differentiate the diagnosis between interstitial and necrotizing pancreatitis because of not allowing the assessment of parenchymal perfusion[21]. EUS can identify choledocholithiasis and hidden pancreatic tumors that remain elusive on CT or MRI in recurrent AP patients. EUS-guided fine needle puncture biopsy can distinguish focal pancreatitis from a pancreatic tumor, and color Doppler US can be used to assess vascular complications such as false arterial aneurysms or portal vein thrombosis[21]. Xu *et al*[91] reported that EUS outperformed CT in accurately categorizing symptomatic peripancreatic fluid collections and emerged as a preferred imaging modality for detecting solid necrotic debris. EUS-guided lumen-apposing metal stents for pancreatic fluid collections were feasible and effective with preferable technical and clinical success rates[92].

In a retrospective analysis with a cohort of 6069 patient, Froes *et al*[93] evaluated the impact of abdominal ultrasound (AUS) on the length of service (LOS) for patients hospitalized for AP who lacked radiographic evidence of AP on CT of the abdomen and pelvis (CTAP). Additionally, they further assessed how AUS affected the probability of subsequent interventions, such as ERCP or cholecystectomy[93]. In patients with AP, undergoing AUS within 48 h resulted in a reduced LOS by 1.099 d. Those who underwent AUS were 1.126 times more likely to proceed with subsequent ERCP compared to those who only had CTAP; patients receiving AUS after CTAP had a 2.711 times higher likelihood of undergoing subsequent cholecystectomy[93]. In this cohort of patients admitted for AP, conducting AUS within 48 h after negative CTAP correlated with reduced LOS. Moreover, patients undergoing AUS were not only more inclined to undergo ERCP but also exhibited a higher likelihood of undergoing cholecystectomy[93].

In a study with a total of 196 patients, Cai *et al*[94] investigated the diagnostic accuracy of US and contrast-enhanced US (CEUS) for AP. They demonstrated that CEUS outperformed US in diagnosing AP and SAP and produced excellent results in the staging of AP severity[94]. In this study, compared to results from CECT, the diagnostic rates for pancreatic swelling using US and CEUS were 121% (148/122) and 91% (111/122), respectively, while for peripancreatic fluid collection, they were 84.8% (151/178) and 96.6% (172/178), respectively[94]. The findings confirmed that CEUS surpassed US in specificity when visualizing pancreatic parenchyma edema, pancreatic border-capsula, collection fluid of peripancreas, and peripancreatic necrosis. This discrepancy between US and CEUS might arise from the ability of CEUS to visualize vessels upon contrast agent injection[94]. The conclusion drawn was that CEUS serves as a trustworthy method for diagnosing and monitoring AP and SAP, potentially acting as an alternative to CECT[94].

***Summary***

The application of imaging in patients with AP is an essential aspect of modern clinical management. While there are challenges associated with their use, continuous research, technological advances, and thoughtful implementation of guidelines can optimize their role in patient management.

Imaging technologies for diagnosing and managing AP have made great strides, but inappropriate imaging tests can increase economic costs to the health system, subject patients to excess radiation, and elevate complication rates without benefiting patients. The choice of appropriate imaging modality for AP depends exactly on available time, technique, and clinical situation of the patient. Although imaging examination is widely used and carefully evaluated during the diagnosis process of AP, it remains unclear when imaging should be performed, especially given the economic costs associated with imaging and the financial burden on patients. In terms of the economic and financial implications of diagnostic imaging for AP patients, early imaging may not be advisable for those presenting with characteristic clinical symptoms and pronounced laboratory results. However, when clinical manifestations are unclear, early imaging examination is often used to identify suspected AP, discover potential etiology, diagnose complications, assess severity, implement risk stratification, and guide treatment. For AP patients, imaging technologies remain pivotal in initial diagnosis, identification of severe cases, assessment of prognosis, and decision of therapeutic management.

Radiomics is a data science technique that extracts a large number of quantitative features from medical images using advanced algorithms. These features capture subtle differences in the texture, shape, and intensity of image regions, which may be difficult for human observers to discern. By extracting these features, radiomics can transform images into high-dimensional data that can be analyzed and mined using machine learning and other data science techniques. This allows for more objective and precise diagnosis, treatment planning, and prognosis evaluation in AP. Therefore, radiomics has the potential to revolutionize medical imaging and improve patient outcomes in the 21st century.

**CLINICAL SCORING SYSTEMS**

Over the decades, many clinical scoring systems have been developed and applied, and their efficacy and accuracy have been compared. Clinically, an ideal scoring system should be responsive, simple, reliable, and universally applicable across diverse patient populations and geographical areas, maintaining its relevance over time. Such clinical scoring systems are imperative to predict complications, severity, mortality, and ICU admission requirements in AP patients[95]. Numerous “traditional” multifactorial clinical scoring systems, such as APACHE II, Ranson, Glasgow, Systemic Inflammatory Response Syndrome (SIRS), HAPS, Japanese Severity Score (JSS), CTSI, Sequential Organ Failure Assessment (SOFA) and BISAP, provide insights into systemic complications to some extent and possess commendable predictive capabilities for severity and mortality of disease[12,82,96-98]. Based on the 2012 RAC, these scoring systems primarily stratified the severity of AP into MAP, MSAP, and SAP[99].

Development of the original APACHE severity-of-illness classification system began in 1978, and APACHE II was derived from the results of a simplified effort based on the 12 most commonly used physiological measures included in the original APACHE system[100]. APACHE II, initially designed for intensive care applications, necessitates the aggregation of numerous parameters, some of which might not be pertinent to the prognosis in AP, while it overlooks key indicators such as pancreatic injury and significant regional complications[101,102].

Ranson was first used to assess the severity of AP in 1974 and has been used for nearly 50 years[103]. Ranson is relatively accurate in classifying the severity of AP patients; however, its limitation is the 48-h duration required for completion, thereby missing a crucial early therapeutic opportunity[102]. The main limitation of Glasgow, much like Ranson, is the need for a 48-h duration to finalize the calculation[96]. However, based on the local characteristics of CT examinations, CTSI mainly emphasizes local complications but falls short in representing the systemic inflammatory response[42]. In addition, for SAP, MCTSI demonstrates prognostic value for short-term mortality, while CTSI effectively predicts the necessity for intervention[104]. SOFA, similar to APACHE II, is a detailed scoring system that takes into account acute and chronic illness, signs, and laboratory values in patients[12].

***Comparison of different scoring systems used in AP***

For a more thorough understanding of the various attributes inherent in distinct scoring systems, we will embark on a comprehensive discussion and detailed analysis of the utilization of commonly employed clinical scoring systems within the context of AP in the following sections.

In two independent, prospectively enrolled cohorts [training (*n* = 256) and validation (*n* = 397)] of AP patients, Mounzer *et al*[105] compared the accuracy of the scoring systems including APACHE II, BISAP, Glasgow, HAPS, JSS, Ranson, and SIRS in predicting persistent organ failure. In this study, they discovered that these scoring systems exhibited moderate accuracy, with area under the curve (AUC) at admission ranging from 0.62-0.84 in the training cohort and 0.57-0.74 in the validation cohort. Notably, Glasgow emerged as the superior classifier at admission in both cohorts[105]. In a retrospective study including 161 patients, statistically significant cutoff values in predicting SAP were APACHE II ≥ 8, Ranson ≥ 3, BISAP ≥ 2, CTSI ≥ 3, and CRP24 ≥ 21.4 mg/dL. APACHE II had the highest accuracy in predicting SAP[106].

Confusingly, different studies have shown that these scoring systems vary widely in accuracy, sensitivity, and specificity for the desired purpose of prediction, as follows. In a retrospective study including 326 patients diagnosed with hyperlipidemic AP (HLAP), the predictive abilities of APACHE II, BISAP, Ranson, and MCTSI were compared for assessing MSAP and SAP, local complications, and HLAP mortality[107]. The results showed that the four scoring systems have their own advantages and characteristics. For example, Ranson lacked a distinct advantage in predicting severity and prognosis of HLAP compared to other three scoring systems. APACHE II excelled in predicting HLAP severity but fell short in predicting local complications. MCTSI demonstrated exceptional prowess in predicting local complications yet was less adept in predicting severity and mortality. BISAP offered a commendable accuracy in evaluating the severity, local complications, and mortality of HLAP, yet there remains room for refining its precision in future assessments[107].

In a prospective study including 50 AP patients, Kumar and Griwan[108] assessed the accuracy of APACHE II, BISAP, Ranson and MCTSI in predicting the severity of AP, referencing the 2012 RAC. In this study, MCTSI demonstrated the highest AUC values for predicting SAP (0.919), pancreatic necrosis (0.993), organ failure (0.893), and ICU admission (0.993); meanwhile, APACHE II ranked second in accuracy for predicting SAP (0.834) and organ failure (0.831)[108]. The findings indicated that APACHE II demonstrated a high sensitivity in predicting pancreatic necrosis (93.33%), organ failure (92.86%), and ICU admission (92.31%) while also maintaining a substantial negative predictive value (NPV) for predicting pancreatic necrosis (96.15%), organ failure (96.15%), and ICU admission (95.83%)[108].

Keskin *et al*[109] retrospectively investigated 690 patients who had been admitted due to AP by five scoring systems including HAPS, Ranson, BISAP, Glasgow, and JSS. In this study, NPV of each score was notably superior to their respective positive predictive value (PPV)[109]. Of the five scoring systems, JSS exhibited the highest value of AUC across all endpoints (0.80 for in-hospital major adverse events, 0.94 for in-hospital mortality, 0.91 for 30-d mortality); nevertheless, none of the five scoring systems effectively predicted 30-d readmission[109].

Li *et al*[110] conducted a retrospective assessment of four scoring systems (Ranson, BISAP, Glasgow, and APACHE II) to predict AP outcomes in 918 patients, categorizing them into two age groups: The elderly (≥ 60-years-old) and the younger (< 60-years-old). In this study, they drew several following conclusions: BISAP effectively predicted the severity, pancreatic necrosis, and mortality in elderly AP patients; APACHE II was more suitable for assessing severity in younger patients; both Ranson and Glasgow were generally applicable for evaluating most AP patients; and Ranson demonstrated heightened efficacy in assessing severity among younger patients[110]. In this study, the criterion of predicting SAP was different between the elderly and the younger (the elderly: Ranson ≥ 4, Glasgow ≥ 3, APACHE II ≥ 9, BISAP ≥ 3; the younger: Ranson ≥ 3, Glasgow ≥ 2, APACHE II ≥ 8, BISAP ≥ 2), suggesting that the scoring cutoffs for the elderly were consistently one point higher than those for the younger[110]. The variation in the cutoff value for predicting SAP enhanced the specificity of the four scoring systems albeit with a marginal reduction in their sensitivity to SAP[110].

In a retrospective analysis including 653 AP patients, Teng *et al*[111] investigated and compared the characteristics of six scores in predicting SAP, ICU admission, and mortality, including Ranson, Glasgow, APACHE II, BISAP, HAPS, and SOFA. In predicting SAP, SOFA exhibited the lowest sensitivity at 13.6% but boasted the highest specificity at 99.7%. Conversely, Ranson maintained the highest sensitivity at 92.6% but had one of the lowest specificities at 51.9%, with only HAPS registering a slightly lower specificity at 49.7%[111]. In predicting ICU admission, APACHE II and Ranson displayed a sensitivity at 100.0%, BISAP demonstrated the lowest sensitivity at 25.0% and a specificity at 93.4%, and SOFA demonstrated the highest specificity at 99.2%[111]. In predicting mortality, APACHE II and Ranson displayed a sensitivity at 100.0%, BISAP showcased the lowest sensitivity at 25.0%, and SOFA had the highest specificity at 98.9%, similar to ICU admission[111]. All scores had high and comparable NPVs in the prediction of SAP, ICU admission, and mortality in AP patients[111]. In this study, they concluded that SOFA and 48-h Ranson outperformed other clinical scorings (Glasgow, APACHE II, BISAP, HAPS) in predicting severity, ICU admission, and mortality[111].

In a prospective observational study including 164 patients, Venkatesh *et al*[112] reported that, based on receiver operating characteristic (ROC) curves, Ranson at admission demonstrated superior diagnostic accuracy in predicting severity, organ failure, and mortality and outperformed the other three scores (APACHE II, BISAP, and modified Glasgow) in predicting AP severity. In addition, this study revealed that while BISAP might be calculated within 24 h of admission, both APACHE II and modified Glasgow demonstrated superior diagnostic accuracy, with APACHE II exhibiting the strongest association with mortality in SAP patients[112].

Asfuroğlu Kalkan *et al*[113] retrospectively analyzed 1150 AP patients, and reported that these scoring systems including BISAP, Ranson, HAPS, APACHE II, and Glasgow were capable of predicting mortality. However, APACHE II predicted mortality with a sensitivity of 90% and specificity of 92%[113].

Drawing on the insights gleaned from the aforementioned body of literature, we have meticulously synthesized a detailed appraisal of the application of various clinical scoring systems in prognosticating severity, local complications, organ failure, and mortality rates associated with AP. These summarizations are comprehensively depicted in Table 1. Various scoring systems exhibited diverse levels of sensitivity, specificity, and accuracy in forecasting the severity, local complications, organ failure, and associated mortality. Further, it is noteworthy that numerous studies have indicated the existence of substantial differences among these scoring systems, highlighting their lack of uniform standards and, in some instances, a concerning degree of inconsistency in their projections. Given the variability in accuracy among diverse scoring systems for predicting the severity, local complications, organ failure, and mortality associated with AP, there is a plausible need for further refinement and design optimization of each scoring system to enhance the precision of these predictions. Moreover, another potential area of research could be the amalgamation of multiple existing scoring systems to boost the predictive accuracy for AP through a more comprehensive scoring approach.

To enhance a more comprehensive understanding of the clinical utility of prevalent scoring systems, such as BISAP, SOFA, and qSOFA, in predicting AP outcomes, we conducted independent discussions and analyses on the latest advancements of these tools to provide invaluable reference and guidance for their practical application in clinical settings.

***BISAP***

In a large population-based study, Wu *et al*[101] identified five variables for prediction of in-hospital mortality by Classification and Regression Tree analysis to derive a prognostic scoring system (BISAP) including blood urea nitrogen (> 25 mg/dL), age (> 60 years), SIRS, pleural effusion, and impaired mental status. Blood urea nitrogen emerged as the most efficient primary discriminative variable, age and SIRS further distinguished between high-risk and low-risk cases, and mental status and pleural effusion further refined the categorization of intermediate-risk patients[101]. Introduced in 2008, BISAP, with its advantages of simplicity and precision, had been employed for the early identification of AP patients with an elevated risk of in-hospital mortality[101]. BISAP is adept at identifying AP patients at heightened risk of mortality, representing the advancement of intermediate markers of severity within 24 h of onset, and its risk stratification ability could hold potential for enhancing clinical care and streamlining enrollment in clinical trials[114]. BISAP was considered to be as good as APACHE II in predicting severity, death, and especially organ failure in AP. It outperformed Ranson, CTSI, CRP, hematocrit, and body mass index, with a score of 2 being a statistically significant cutoff value[115]. BISAP is a streamlined scoring system designed to predict the severity of AP and is instrumental in early risk stratification of AP.

A prospective study of 87 patients experiencing their first episode of AP revealed that BISAP (≥ 2) demonstrated comparability to both APACHE II (≥ 8) and MCTSI (≥ 8) in metrics of accuracy, sensitivity, specificity, and NPV[116]. In a systematic review and meta-analysis, a pooled analysis from 12 prospective cohorts showcased the exemplary performance of BISAP in predicting SAP across diverse patient populations and disease severity[117]. Furthermore, the performance of BISAP was notably superior when severe pancreatitis was characterized by the persistence of organ failure for 48 h or more[117]. A European cohort study indicated that BISAP effectively predicted SAP, mortality, and ICU admission, making it invaluable for triaging patients toward ICU care[118].

Chen *et al*[119] assessed the accuracy of BISAP in predicting the severity and prognoses of AP in Chinese patients. In this study, they retrospectively analyzed clinical data from 497 AP patients comparing BISAP with APACHE II, Ranson, and CTSI regarding their predictive capacities for the severity of AP and the occurrence of mortality, pancreatic necrosis, and organ failure in SAP patients[119]. They highlighted that BISAP outperformed traditional scoring systems in terms of simplicity and speed, and maintained a performance comparable to other scoring systems in predicting both SAP and its associated prognoses[119].

Zhang *et al*[120] evaluated the efficacy of BISAP, APACHE II, and Ranson in predicting the severity, mortality, and pancreatic necrosis of AP based on the 2012 RAC at a tertiary care center in China. From their study involving 155 patients, they determined that BISAP might serve as a reliable tool for risk stratification and prognostic assessment in Chinese AP patients[120]. Gao *et al*[121] conducted a meta-analysis to systematically assess the accuracy of BISAP in predicting mortality and SAP and affirmed that BISAP served as a dependable tool for identifying AP patients at elevated risk for adverse outcomes. While BISAP demonstrated superior specificity compared to Ranson and APACHE II, it exhibited a slightly diminished sensitivity for both mortality and SAP[121].

An Indian study with 119 AP patients showed that BISAP was an accurate means of risk stratification, and patients with BISAP ≥ 4 invariably developed SAP or pancreatic necrosis and had high mortality[122]. The available studies collectively demonstrated that BISAP performs very well in predicting SAP, and the simplicity and accuracy of the calculation make BISAP a valuable tool for clinical care of AP patients. Additionally, before confidently advocating for the adoption of BISAP, its integration into clinical practice should be evaluated to determine its potential to enhance outcomes in AP.

BISAP, an easily computed clinical prediction scale, leverages data from initial assessment of patients and routine laboratory results, demonstrating excellent performance in predicting SAP. BISAP is less cumbersome to calculate and more economical, which makes it an ideal scoring system. It is considered that BISAP should be popularized at primary and secondary care institutions for severity classification and risk stratification of early AP. Therefore, SAP patients can be referred to higher-level medical centers for more reasonable clinical intervention.

However, as more and more clinical studies have been conducted, BISAP has shown inconsistent predictive power and results in predicting SAP, as reported in the next studies. A prospective study including 51 patients showed that BISAP was inferior to APACHE II in predicting the severity of AP, especially for SAP[123]. In a meta-analysis including 1972 subjects, Yang and Li evaluated the diagnostic performance of BISAP in predicting SAP[124]. They concluded that despite its high specificity BISAP was not the optimal standalone method for assessing AP severity due to its low sensitivity[124].

In a prospective study including 50 AP patients, the accuracy of BISAP in predicting SAP was 84%, surpassing that of serum procalcitonin (PCT) (≥ 3.29 ng/mL) at 76%, which was on par with APACHE II; moreover, in logistic regression analysis, BISAP demonstrated greater statistical significance than serum PCT[125]. They determined that BISAP outperformed serum PCT, APACHE II, Glasgow, and BCTSI in accurately predicting AP severity, positioning it as a promising tool for gauging the clinical progression of AP[125]. Hagjer *et al*[126] evaluated the usefulness of BISAP and PCT for AP prediction in a prospective observational study including 60 patients. Based on this study, in predicting severity, mortality, and organ failure, they finally concluded that BISAP was as effective as APACHE II and surpassed Ranson, CTSI, CRP, hematocrit, and body mass index in evaluating AP patients. PCT was a good independent prognostic marker and was comparable with BISAP and APACHE II in accuracy[126].

A multicenter validation study is essential to corroborate these findings and further elucidate the role of BISAP in AP. Meanwhile, further well-designed prospective studies are warranted to investigate the conditions under which BISAP can be used to more accurately, sensitively, and specifically assess severity and prognosis in AP.

***Combination of BISAP and other diagnostic indicators***

In a retrospective analysis including 114 cases, the severity and mortality of AP escalated with the increase of BISAP, and BISAP exhibited a positive correlation with CRP, D-dimer, and serum glucose and negatively correlated with serum Ca2+[127]. Based on the positive correlation between CRP and APACHE-II, Ranson, BISAP, and CTSI, when CRP was included into BISAP, the AUC of predicting SAP and death were 0.873 and 0.909, respectively, showing that the combination of BISAP and CRP had better predictive value for severity and death of AP[127]. In a study including 117 SAP patients, Wu *et al*[128] reported that combining BISAP with miR-155 yielded a superior AUC compared to individual predictions, suggesting that this combination could enhance the clinical predictive accuracy for AP severity.

Early diagnosis and timely assessment of the severity are critical because early aggressive treatment reduces morbidity and mortality of AP. However, an ideal multifactor scoring system for early assessment of AP severity has not been determined. Based on an analysis of the available data and evidence, we recommend that BISAP as a multifactor scoring system is combined with characteristic biochemical markers present at 48 h, in order to achieve optimal early assessment of AP severity.

***SOFA***

In October 1994, the European Society of Intensive Care Medicine convened in Paris to establish the SOFA score, aiming to quantitatively and objectively describe the degree of organ dysfunction/failure over time in patient groups or even in individual cases[129]. Although SOFA is primarily designed for patients with sepsis, it was deemed necessary to expand its application beyond this specific patient group[129]. At present, SOFA is widely utilized in the ICU to evaluate, prognosticate, and assess patients; since its validation, it has been applied in diverse medical settings, including trauma, surgical, cardiac, and neurological ICUs[130].

Minne *et al*[131] conducted a systematic review on the utility of SOFA-based models for predicting the risk of mortality in ICU patients and recommended an integration of a traditional model derived from data within the initial 24 h post-ICU admission with sequential SOFA. SOFA could be easily integrated into contemporary cardiac ICU through an electronic algorithm, and the day 1 SOFA demonstrated strong predictive capability for short-term mortality among a broad spectrum of patients in the cardiac ICU[132]. Among the critical care systems, SOFA has distinct benefits, including its simplicity in computation, incorporation of therapeutic needs, and facilitation of comparisons of AP with other critical care diseases[24].

Adam *et al*[133] retrospectively evaluated the efficacy of APACHE II, SOFA, and modified Ranson in predicting mortality among 43 SAP patients as well as other factors influencing mortality in patients admitted to the ICU and concluded that SOFA was superior to Ranson and APACHE II in determining prognosis. In this study, SOFA had a significant correlation with mortality, and all patients with SOFA ≥ 11 at any point during the ICU stay exhibited a heightened mortality risk, with a sensitivity of 80% and a specificity of 79%[133].

Tee *et al*[134] retrospectively obtained serial measurements of Ranson, APACHE II, and SOFA in 159 patients with SAP, assessing the efficacy of serial measurement using these three scoring systems. In this study, besides acquiring Ranson and APACHE II on admission and at 48  h, they took serial weekly measurements of SOFA, including data from admission, 48  h, and days 7, 14, and 21[134]. The three scoring systems reliably predicted both overall and ICU mortality. However, the SOFA on day 7 exhibited the largest AUC, with any increase or lack of change in SOFA on day 7 of hospitalization correlating with elevated mortality[134]. They concluded that both APACHE II and SOFA were sensitive in predicting mortality for AP. Serial SOFA proved reliable for guiding clinical decisions, and day 7 of hospitalization was a reasonable time for SOFA reassessment to predict late mortality in SAP[134].

A retrospective study enrolling 146 AP patients demonstrated that an increase in SOFA independently heightened the likelihood of adverse outcomes during hospitalization for AP patients, and SOFA > 5 was highly predictive of in-hospital mortality compared to other scores[135]. Utilizing a straightforward tool like SOFA, validated in intensive care settings, could enhance the stratification of in-hospital mortality risk and clinical deterioration among AP patients admitted to medical wards. Teng *et al*[111] reported that both SOFA and 48-h Ranson effectively predicted the severity, ICU admission, and mortality associated with AP, with SOFA showing particularly favorable results.

***qSOFA***

The qSOFA includes respiratory rate (breaths per minute), systolic blood pressure (mm Hg), and Glasgow Coma Scale score[136]. In a 17-year observation study including 1059 patients, the ROC curve analysis revealed that the AUC values of APACHE II, SOFA, and qSOFA scores in predicting the prognosis of infected patients were 0.713, 0.744, and 0.662, respectively[137]. In this study, Qin *et al*[137] posited that qSOFA, due to its advantages of rapid acquisition, would serve as an efficient tool for assessing the prognosis of ICU patients with infections. Given its extraordinary simplicity, qSOFA would be an appropriate score particularly for the initial patient evaluation in the emergency department and was considered to be a rapidly available prognostic score in AP with limited prognostic validity[138]. In a cohort study including 203 patients, Rasch *et al*[138] reported that qSOFA could predict ICU admission and multiple organ dysfunction syndrome in AP.

In a retrospective cohort study involving 161 patients with the diagnosis of alcohol-induced AP, a qSOFA score of 2 or higher both upon admission and 48 h post-admission exhibited a specificity of 94% or greater and sensitivity of 33% or higher for assessing pancreatitis severity and determining the necessity for intensive care admission, intubation, or vasopressor[139]. In a 3-year cohort study from the United States, Hallac *et al*[140] evaluated the ability of qSOFA and SIRS in predicting extended hospital stays among patients presenting with AP to the emergency department and hospital ward. A qSOFA of 2 or higher was linked to a diagnosis of significant AP with a specificity of 99% and a sensitivity of 4%. In contrast, a SIRS score of 2 displayed a specificity of 61% and a sensitivity of 80% in detecting patients with significant AP[140]. Based on their findings, they inferred that relying solely on qSOFA for triaging AP patients could lead to under recognition and potential undertreatment[140].

***HAPS***

HAPS was calculated rapidly from the following three parameters: presence or absence of rebound tenderness or guarding; hematocrit (> 43 mg/dL for males or > 39.6 mg/dL for females); and serum creatinine (> 2 mg/dL)[105,141]. Oskarsson *et al*[142] reported that HAPS predicting nonsevere AP progression had a specificity of 96.3% and a corresponding PPV of 98.7% in 531 patients experiencing either a first-time or a recurrent attack of AP, emphasizing HAPS as a highly specific scoring algorithm predicting nonsevere AP progression[142]. In a prospective pilot study with 103 AP patients from India, the sensitivity, specificity, PPV, NPV, and AUC of HAPS as a predictor of nonsevere disease were 76.3%, 85.7%, 93.8%, 56.6%, and 0.848, respectively[143]. In a study including 703 AP patients from China, the sensitivity, specificity, PPV, NPV, and AUC of HAPS on admission for predicting MAP was 48.2%, 97.7%, 95.6%, 64.1%, and 0.749, respectively[97]. These studies validated the utility of HAPS at admission in predicting nonsevere AP in India and MAP in China, respectively. Maisonneuve *et al*[144] evaluated the PPV of HAPS by performing a meta-analysis of 20 reports covering 6374 patients. They concluded that HAPS accurately identified patients with nonsevere AP who would not require ICU care, enabling the pinpointing of patients suitable for brief general ward stays or home-based care[144].

HAPS may offer significant advantages in the triage of AP patients when compared to other scoring systems, underscoring its potential utility in optimizing patient classification and guiding treatment strategies. In a study including 60 patients with the first attack of AP, Gupta *et al*[145] reported that the sensitivity, specificity, PPV, NPV, and AUC of HAPS predicting SAP were 90.91%, 59.81%, 33.33%, 96.67%, and 0.75, respectively. The high NPV indicated that HAPS could very accurately identify within the first hour of admission patients who had a mild course of disease, did not require intensive management, and were not at risk of dying from the disease[145]. Based on this result, they argued that the patient typically tended to experience a milder course of illness if the evaluation of HAPS yielded a negative result[145]. Conversely, in instances where the score was positive, the patient’s clinical progression could unfold in any direction, demonstrating the uncertainty associated with such an outcome[145]. In this same study, the sensitivity, specificity, PPV, NPV, and AUC of BISAP in the prediction of SAP were 63.64%, 100%, 100%, 92.45%, and 0.82, respectively[145]. In comparison to BISAP in this study, HAPS demonstrated a heightened sensitivity towards processes predicting mortality and severity and played a pivotal role in determining whether patients necessitated costly imaging procedures, thereby potentially enabling significant hospital cost savings[145]. In a study with 116 patients, Al-Qahtani *et al*[146] compared HAPS with Ranson in predicting the severity of AP and concluded that HAPS was effective in rapidly identifying patients likely to experience a nonsevere course of the disease.

Of significant importance is the fact that assessment of HAPS can be accomplished within the first hour of a patient visit, offering a distinct advantage in terms of time efficiency. In contrast, while Ranson might offer superior accuracy, it necessitates a full 48 h to reach completion, highlighting a potential trade-off between speed and precision in these scoring systems. Considering that the substantial majority of individuals diagnosed with AP typically exhibit a milder form of the disease, the capacity to accurately distinguish these patients of MAP is of utmost significance. Drawing upon the aforementioned analysis and discussion, HAPS appears to be a commendable choice for assisting physicians in evaluating the severity of AP. Furthermore, HAPS could potentially be perceived as a gold standard for facilitating both the early identification and cost-effective management of this disease. In addition, due to the readily accessible parameters required for its computation, HAPS can be effectively utilized in a wide range of healthcare facilities, including those located in developing countries. This ease of implementation makes HAPS an inclusive and practical tool for global health contexts.

***Other recent clinical scoring systems***

Hong *et al*[147] developed a prognostic score termed SABP, encompassing systemic inflammatory response syndrome, serum albumin, blood urea nitrogen, and pleural effusion. The SABP score could serve as an instrumental tool to categorize patients at risk of developing SAP as per the latest revised Atlanta criteria. Its application on admission may enhance clinical care and refine management approaches for AP[147]. He *et al*[148] retrospectively analyzed the clinical data of 469 patients with AP, and selected seven prognostic indicators to establish an unweighted predictive score and weighted predictive score for MSAP and SAP. The early multi-indicator prediction models for MSAP and SAP demonstrated robust predictive efficacy, offering a meaningful clinical benchmark for diagnosis and treatment[148].

In a retrospective analysis encompassing a total of 1295 AP patients, Feng *et al*[149] developed an independent predictive tool, known as a nomogram, to predict the likelihood of sepsis occurrence in this patient population. In this study, the predictive performance and clinical utility of the newly established nomogram surpassed those of other scoring systems such as SIRS, BISAP, SOFA, and qSOFA[149]. The innovative risk-prediction system could precisely estimate the likelihood of sepsis in AP patients, assisting clinicians in formulating personalized treatment strategies for the patients. By doing so, it not only alleviated the disease burden of the patients but also facilitated the reasonable distribution of medical resources, which was a crucial aspect of tertiary prevention[149]. The nomogram incorporated all the independent prognostic factors, including body temperature, phosphate, Ca2+, sodium, lactate, albumin, platelet count, urinary output, mean blood pressure, Glasgow Coma Scale, and Charlson Comorbidity Index[149]. These diverse elements collectively contributed to its predictive strength.

***Summary***

Score systems, utilizing 4-25 factors, have been developed to predict severity, yet they frequently rely on multiple parameters not measurable daily and often require over 24 h to finalize, leading to critical time loss[150]. While these scores can predict failure or severity of specific organs, their reliance on dichotomous parameters leads to information loss, limiting their practical application in clinical settings[150]. Based on the current literature, here are the identified problems and potential solutions for applying clinical scoring systems to the diagnosis, severity prediction, and prognosis assessment of AP.

**Inconsistency:** Different scoring systems like Ranson, Glasgow, BISAP, and CTSI may yield inconsistent results, leading to confusion in clinical decision-making.

Solution: Research to validate and compare different scoring systems can help identify the most accurate and reliable ones. Standardizing the use of a particular scoring system across healthcare settings can reduce inconsistency.

**Complexity:** Some scoring systems are complex and require multiple parameters, making them time-consuming to calculate. This complexity can hinder their practical application in urgent care settings.

Solution: Creating simplified and user-friendly scoring systems that maintain accuracy can make them more practical for clinicians to use, especially in urgent care settings.

**Lack of** **sensitivity and specificity:** Some scoring systems may lack sensitivity or specificity in predicting the severity and prognosis of AP, leading to inaccurate assessments.

Solution: Combining scoring systems with comprehensive clinical assessment can lead to more accurate care. This solution is more of a clinical recommendation rather than a documented research finding.

**Lack of personalization:** Scoring systems are often based on population-level data and may not account for characteristics of individual patient, leading to generalized predictions that may not be applicable to all patients.

Solution:Considering patient-specific factors, such as comorbidities, lifestyle, and preferences, in conjunction with scoring systems, can lead to more personalized and effective care.

**Over-reliance on scoring systems:** Sole reliance on scoring systems without considering clinical judgment and other patient-specific factors may lead to suboptimal care.

Solution: Providing education and training to healthcare professionals on how to effectively use scoring systems, including their limitations, can enhance their application in clinical practice.

In conclusion, while clinical scoring systems are valuable tools in managing AP, they present challenges that are recognized both in clinical practice and in the research literature. The solutions outlined above, grounded in current research and clinical wisdom, can enhance the effectiveness of these systems in providing accurate and personalized treatment for patients with AP.

**AI**

In the era of AI, machine learning algorithms have been devised to accurately predict the severity, complications, recurrence, mortality, and even the optimal timing of surgery for AP patients. However, the quality of research evaluating the accuracy of AI is still low and lacks studies comparing AI with these commonly used clinical scores. Therefore, more research is needed before we can routinely use AI in our daily clinical practice. Prior to this, the easy-to-calculate and applicable scoring systems seems to be the most reasonable choice.

Recently, AI applications, utilizing machine learning, have been progressively integrated into the medical field, demonstrating superior performance in predicting complications compared to logistic regression analysis[151]. AI-based machine learning is booming and creating a technological revolution, especially in the healthcare industry[152]. Machine learning, a subset of AI, employs statistical methods to train algorithms for predictions, enabling a computer system to self-learn and enhance its performance based on experience[150]. Machine learning has garnered significant attention and recognition from clinicians, driven by advancements in statistical theory and computer technology[153]. Machine learning adeptly discerns intricate relationships between diseases and variables, categorizes variables based on specific criteria, predicts outcomes from foundational features, and recognizes objects with analogous patterns[152]. Innovative machine learning technologies have been extensively employed in predictive models for a spectrum of diseases, consistently demonstrating superior performance over traditional logistic regression or Cox regression analyses[153].

In this age of technological advancement, AI stands as a pinnacle of innovation, proficiently discerning the intricate non-linear proficiently between numerous biochemical parameters and their associated disease outcomes[150]. For example, a retrospective study demonstrated that when juxtaposed with the traditional logistic regression model machine learning models [extreme gradient boosting (XGBoost) and random forest (RF)] utilizing readily accessible features upon admission exhibited superior performance in predicting acute kidney injury among AP patients[151]. Leveraging such machine learning algorithms in predictive models could enable clinicians to foresee acute kidney injury at an early stage, potentially mitigating further renal damage[151].

Based on an international cohort of 1184 patients and a validation cohort of 3543 patients, Kui *et al*[154] devised a user-friendly web application named EASY-APP, which employs multiple continuous variables accessible at admission. The EASY prediction score serves as an effective tool for pinpointing patients at elevated risk for severe AP within hours of hospitalization, and the web application was made available to clinicians, enhancing the utility and precision of the model[154].

Zhou *et al*[155] demonstrated that the XGBoost algorithm possesses the capability to precisely predict the severity of AP, offering clinicians valuable assistance in identifying severe AP at an early stage. In a prospective cohort study integrating necrosis prediction with AI, the XGBoost machine learning algorithm was employed to analyze the data from 2387 AP patients[156]. This model in the predictive capability rivals those existing clinical scoring systems, and its performance is anticipated to improve with continued use[156]. In the United States, Thapa *et al*[7] applied machine learning algorithms to predict which AP patients need SAP treatment and developed three models using logistic regression, neural networks, and XGBoost. In this study, machine learning models were trained and tested to utilize data from 61894 patients, with the XGBoost model surpassing the performance of both logistic regression and neural network-based models[7]. Furthermore, the XGBoost model achieved a superior AUROC compared to both HAPS and BISAP in identifying patients likely to be diagnosed with SAP[7]. They concluded that machine learning has the potential to refine the precision of AP risk stratification methods, facilitating prompter treatment and intervention initiation[7].

In a large retrospective study enrolling 5460 patients, Yuan *et al*[157] developed and validated a novel machine learning tool, APCU, leveraging clinical, laboratory, and radiologic data to predict ICU admission among AP patients. They showed that the APCU effectively categorized AP patients into high-risk and low-risk groups, demonstrating a superior discriminative capability compared to other risk scores like Ranson, APACHE II, SIRS, and NEWS in predicting ICU admission for AP patients and specific subgroups within 48 h of hospitalization[157]. Notably, this study marked the inaugural application of a machine learning algorithm for the predictions of ICU admission in AP patients within 48 h of hospitalization, relying on widely accessible clinical, laboratory, and radiologic data[157].

In a retrospective analysis involving 648 AP patients, Hong *et al*[158] developed RF and logistic regression models using a training sample; the RF model, notable for its interpretability, showcased the most superior discriminative performance in predicting SAP. In a retrospective study involving 631 AP patients, Luo *et al*[159] developed a machine learning model, culminating in a nomogram designed for the early identification of SAP during the progression of AP. Their findings indicated that the RF model delivered optimal predictive performance, with the nomogram offering a visual scoring model suitable for clinical application[159]. Such models have the potential to act as functional tools, enabling personalized treatment choices and enhancing clinical results by stratifying AP patients prior to treatment[159]. In a study with a total of 1012 patients, Yin *et al*[160] developed a series of effective models for early prediction of SAP based on automated machine learning (AutoML) platform, and these models outperformed the existing scoring systems, which might offer insights into AutoML applications in future medical studies. The AutoML model based on the GBM algorithm for early prediction of SAP showed evident clinical practicability[160].

In a recent retrospective study involving a cohort of 460 AP patients to predict ARDS in these patients at admission, Zhang *et al*[161] constructed and optimized four machine learning models, including support vector machine, ensembles of decision trees (EDTs), Bayesian classifier (BC), and nomogram models, based on 31 features with significant differences between the groups with and without ARDS. Among the four models, the BC algorithm exhibited superior predictive performance with the highest AUC (0.891), surpassing support vector machine (0.870), EDTs (0.813), and the nomogram (0.874) in the test set[161]. Concurrently, the EDT algorithm achieved the highest accuracy at 0.891, precision at 0.800, and F1 score at 0.615 but registered the lowest FDR at 0.200 and the second-highest NPV at 0.902[161]. In terms of predictive performance for ARDS as a complication of AP, they concluded that BC was the superior predictive model in the test set, and EDTs exhibited promising potential for predicting large samples[161].

***Summary***

The application of AI in the diagnosis, severity prediction, and prognosis assessment of AP represents an exciting development in the field of medicine. However, based on these current studies, we recognize several limitations and potential challenges that must be addressed to fully leverage the capabilities of AI in this context.

**Data quality and availability:** AI algorithms require high-quality, comprehensive, and diverse data to build robust and accurate models. In the context of AP, such data sets may not be readily available, especially for rare subtypes of the disease or patient populations with specific comorbidities. Furthermore, incomplete or inconsistent data can lead to biased or flawed results.

**Interpretability:** AI models, especially those employing complex algorithms like deep learning, often operate as ‘black boxes,’ providing outputs without clear, understandable reasons for their decisions. This can limit their acceptance in the clinical setting, as healthcare professionals typically prefer to understand the reasoning behind a diagnosis or prediction.

**Standardization:** AI algorithms are typically designed and validated on specific datasets. Their generalizability to other populations or healthcare settings, especially those that are vastly different from the original context, is not guaranteed. This lack of standardization can lead to inconsistent results when the models are used in different settings.

**Generalizability:** Models trained on a specific set of data may not perform well when applied to different datasets, especially if there are demographic or geographical differences. For example, an AI model trained on data from a high-income country might not work as well in a low-income setting due to differences in healthcare infrastructure, disease prevalence, and patient characteristics.

**Regulation:** The use of patient data to develop and apply AI models raises significant concerns around data privacy, consent, and security. It is crucial that these concerns are addressed to ensure ethical usage and maintain public trust. For instance, who is responsible if an AI system makes an incorrect diagnosis or prognosis? How is patient data privacy ensured?

**Implementation:** The successful implementation of AI in healthcare settings requires clinicians to have a certain level of understanding and trust in the technology. This can be challenging due to varying levels of digital literacy among healthcare providers and resistance to change.

Given these challenges, ongoing research is critical to improve the reliability, interpretability, and generalizability of AI tools in healthcare and to address the ethical, legal, and workflow integration issues associated with their use. It is important that as we move forward, these tools are developed and used in a manner that complements the expertise of healthcare professionals rather than seeking to replace it.

**CONCLUSION**

Early aggressive treatment of AP has been proven to reduce the incidence and mortality rates. Therefore early diagnosis and severity assessment of AP are extremely necessary, and there is a particular need for early technological approaches to evaluate and predict the progression of AP.

In recent years, there has been heightened interest in leveraging imaging technologies, scoring systems, and AI to improve the diagnosis, severity prediction, and prognosis evaluation of AP. Different imaging modalities, such as CT, MRI, and US, are used to assess the severity and extent of pancreatic inflammation and detect any complications that may arise. Several scoring systems have been developed to assess the severity of AP and predict the risk of complications, such as Ranson, APACHE II, BISAP, SOFA, and HAPS. These scoring systems take into account various clinical and laboratory parameters, such as age, blood pressure, serum glucose, and white blood cell count, to provide a numerical score that reflects the severity of the disease. AI is a rapidly developing field that has the potential to revolutionize the diagnosis and management of AP. AI algorithms can be trained to analyze large datasets of imaging and clinical data to predict the severity and prognosis of AP. AI algorithms have been developed to analyze CT scans of patients with AP to predict the risk of complications such as pancreatic necrosis, abscess, or pseudocyst. The algorithms can detect subtle changes in the pancreas that may be missed by human radiologists and can provide more accurate and timely predictions of the risk of complications.

The integration of imaging technologies, scoring systems, and AI in the diagnosis, severity prediction, and prognosis assessment of AP has several advantages, including: (1) More accurate diagnosis. Imaging technologies and AI algorithms can provide more accurate diagnoses, reducing the risk of misdiagnosis and unnecessary treatment; (2) Improved risk assessment. Scoring systems and AI algorithms can provide more accurate risk assessments, which can help healthcare providers make more informed treatment decisions; (3) Personalized treatment. The combination of imaging technologies, scoring systems, and AI can provide a more personalized approach to treatment, taking into account each patient’s unique circumstances; and (4) Improved patient outcomes. The earlier and more accurate diagnosis, as well as the more personalized treatment options, can lead to improved patient outcomes and reduced healthcare costs.

Despite these advantages, there are several challenges that need to be addressed when integrating imaging technologies, scoring systems, and AI in the management of AP. These challenges include the need for standardized imaging protocols and scoring systems, the need for large datasets of imaging and clinical data to train AI algorithms, and ethical and legal challenges associated with the use of AI in healthcare. In conclusion, the integration of imaging technologies, scoring systems, and AI has the potential to revolutionize the diagnosis, severity prediction, and prognosis assessment of AP.

**REFERENCES**

1 **Cunha EF**, Rocha Mde S, Pereira FP, Blasbalg R, Baroni RH. Walled-off pancreatic necrosis and other current concepts in the radiological assessment of acute pancreatitis. *Radiol Bras* 2014; **47**: 165-175 [PMID: 25741074 DOI: 10.1590/0100-3984.2012.1565]

2 **Ouyang G**, Pan G, Liu Q, Wu Y, Liu Z, Lu W, Li S, Zhou Z, Wen Y. The global, regional, and national burden of pancreatitis in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *BMC Med* 2020; **18**: 388 [PMID: 33298026 DOI: 10.1186/s12916-020-01859-5]

3 **Siregar GA**, Siregar GP. Management of Severe Acute Pancreatitis. *Open Access Maced J Med Sci* 2019; **7**: 3319-3323 [PMID: 31949538 DOI: 10.3889/oamjms.2019.720]

4 **Petrov MS**, Yadav D. Global epidemiology and holistic prevention of pancreatitis. *Nat Rev Gastroenterol Hepatol* 2019; **16**: 175-184 [PMID: 30482911 DOI: 10.1038/s41575-018-0087-5]

5 **Iannuzzi JP**, King JA, Leong JH, Quan J, Windsor JW, Tanyingoh D, Coward S, Forbes N, Heitman SJ, Shaheen AA, Swain M, Buie M, Underwood FE, Kaplan GG. Global Incidence of Acute Pancreatitis Is Increasing Over Time: A Systematic Review and Meta-Analysis. *Gastroenterology* 2022; **162**: 122-134 [PMID: 34571026 DOI: 10.1053/j.gastro.2021.09.043]

6 **Gapp J**, Hall AG, Walters RW, Jahann D, Kassim T, Reddymasu S. Trends and Outcomes of Hospitalizations Related to Acute Pancreatitis: Epidemiology From 2001 to 2014 in the United States. *Pancreas* 2019; **48**: 548-554 [PMID: 30946239 DOI: 10.1097/MPA.0000000000001275]

7 **Thapa R**, Iqbal Z, Garikipati A, Siefkas A, Hoffman J, Mao Q, Das R. Early prediction of severe acute pancreatitis using machine learning. *Pancreatology* 2022; **22**: 43-50 [PMID: 34690046 DOI: 10.1016/j.pan.2021.10.003]

8 **Lou D**, Shi K, Li HP, Zhu Q, Hu L, Luo J, Yang R, Liu F. Quantitative metabolic analysis of plasma extracellular vesicles for the diagnosis of severe acute pancreatitis. *J Nanobiotechnology* 2022; **20**: 52 [PMID: 35090480 DOI: 10.1186/s12951-022-01239-6]

9 **Fu B**, Feng H, Gao F, Fu X. Role of Extrapancreatic Necrosis Volume in Assessing the Severity and Predicting the Outcomes of Severe Acute Pancreatitis. *Int J Gen Med* 2021; **14**: 9515-9521 [PMID: 34916833 DOI: 10.2147/IJGM.S338658]

10 **Lee PJ**, Papachristou GI. Management of Severe Acute Pancreatitis. *Curr Treat Options Gastroenterol* 2020; **18**: 670-681 [PMID: 33230385 DOI: 10.1007/s11938-020-00322-x]

11 **Banks PA**, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. *Gut* 2013; **62**: 102-111 [PMID: 23100216 DOI: 10.1136/gutjnl-2012-302779]

12 **Chan KS**, Shelat VG. Diagnosis, severity stratification and management of adult acute pancreatitis-current evidence and controversies. *World J Gastrointest Surg* 2022; **14**: 1179-1197 [PMID: 36504520 DOI: 10.4240/wjgs.v14.i11.1179]

13 **Purschke B**, Bolm L, Meyer MN, Sato H. Interventional strategies in infected necrotizing pancreatitis: Indications, timing, and outcomes. *World J Gastroenterol* 2022; **28**: 3383-3397 [PMID: 36158258 DOI: 10.3748/wjg.v28.i27.3383]

14 **Jia YC**, Ding YX, Mei WT, Wang YT, Zheng Z, Qu YX, Liang K, Li J, Cao F, Li F. Extracellular vesicles and pancreatitis: mechanisms, status and perspectives. *Int J Biol Sci* 2021; **17**: 549-561 [PMID: 33613112 DOI: 10.7150/ijbs.54858]

15 **Zheng Z**, Ding YX, Qu YX, Cao F, Li F. A narrative review of acute pancreatitis and its diagnosis, pathogenetic mechanism, and management. *Ann Transl Med* 2021; **9**: 69 [PMID: 33553362 DOI: 10.21037/atm-20-4802]

16 **Forsmark CE**, Baillie J; AGA Institute Clinical Practice and Economics Committee; AGA Institute Governing Board. AGA Institute technical review on acute pancreatitis. *Gastroenterology* 2007; **132**: 2022-2044 [PMID: 17484894 DOI: 10.1053/j.gastro.2007.03.065]

17 **Gumaste VV**, Roditis N, Mehta D, Dave PB. Serum lipase levels in nonpancreatic abdominal pain versus acute pancreatitis. *Am J Gastroenterol* 1993; **88**: 2051-2055 [PMID: 7504396]

18 **Kemppainen EA**, Hedström JI, Puolakkainen PA, Sainio VS, Haapiainen RK, Perhoniemi V, Osman S, Kivilaakso EO, Stenman UH. Rapid measurement of urinary trypsinogen-2 as a screening test for acute pancreatitis. *N Engl J Med* 1997; **336**: 1788-1793 [PMID: 9187069 DOI: 10.1056/NEJM199706193362504]

19 **Treacy J**, Williams A, Bais R, Willson K, Worthley C, Reece J, Bessell J, Thomas D. Evaluation of amylase and lipase in the diagnosis of acute pancreatitis. *ANZ J Surg* 2001; **71**: 577-582 [PMID: 11552931 DOI: 10.1046/j.1445-2197.2001.02220.x]

20 **Hu J**, Chen J, Xu G. Hyperamylasemia of Abnormally Elevated Serum Amylase: Macroamylasemia in a Healthy Individual. *Clin Lab* 2021; **67**: 1091-1094 [PMID: 33865250 DOI: 10.7754/Clin.Lab.2020.200827]

21 **Türkvatan A**, Erden A, Türkoğlu MA, Seçil M, Yener Ö. Imaging of acute pancreatitis and its complications. Part 1: acute pancreatitis. *Diagn Interv Imaging* 2015; **96**: 151-160 [PMID: 24512896 DOI: 10.1016/j.diii.2013.12.017]

22 **Yadav D**, Agarwal N, Pitchumoni CS. A critical evaluation of laboratory tests in acute pancreatitis. *Am J Gastroenterol* 2002; **97**: 1309-1318 [PMID: 12094843 DOI: 10.1111/j.1572-0241.2002.05766.x]

23 **Szatmary P**, Grammatikopoulos T, Cai W, Huang W, Mukherjee R, Halloran C, Beyer G, Sutton R. Acute Pancreatitis: Diagnosis and Treatment. *Drugs* 2022; **82**: 1251-1276 [PMID: 36074322 DOI: 10.1007/s40265-022-01766-4]

24 **Alsfasser G**, Rau BM, Klar E. Scoring of human acute pancreatitis: state of the art. *Langenbecks Arch Surg* 2013; **398**: 789-797 [PMID: 23680979 DOI: 10.1007/s00423-013-1087-0]

25 **Walkowska J**, Zielinska N, Karauda P, Tubbs RS, Kurtys K, Olewnik Ł. The Pancreas and Known Factors of Acute Pancreatitis. *J Clin Med* 2022; **11**: 5565 [PMID: 36233433 DOI: 10.3390/jcm11195565]

26 **Bollen TL**, van Santvoort HC, Besselink MG, van Es WH, Gooszen HG, van Leeuwen MS. Update on acute pancreatitis: ultrasound, computed tomography, and magnetic resonance imaging features. *Semin Ultrasound CT MR* 2007; **28**: 371-383 [PMID: 17970553 DOI: 10.1053/j.sult.2007.06.002]

27 **Raghuwanshi S**, Gupta R, Vyas MM, Sharma R. CT Evaluation of Acute Pancreatitis and its Prognostic Correlation with CT Severity Index. *J Clin Diagn Res* 2016; **10**: TC06-TC11 [PMID: 27504376 DOI: 10.7860/JCDR/2016/19849.7934]

28 **Expert Panel on Gastrointestinal Imaging**, Porter KK, Zaheer A, Kamel IR, Horowitz JM, Arif-Tiwari H, Bartel TB, Bashir MR, Camacho MA, Cash BD, Chernyak V, Goldstein A, Grajo JR, Gupta S, Hindman NM, Kamaya A, McNamara MM, Carucci LR. ACR Appropriateness Criteria® Acute Pancreatitis. *J Am Coll Radiol* 2019; **16**: S316-S330 [PMID: 31685100 DOI: 10.1016/j.jacr.2019.05.017]

29 **Brizi MG**, Perillo F, Cannone F, Tuzza L, Manfredi R. The role of imaging in acute pancreatitis. *Radiol Med* 2021; **126**: 1017-1029 [PMID: 33982269 DOI: 10.1007/s11547-021-01359-3]

30 **Lohse MR**, Ullah K, Seda J, Thode HC Jr, Singer AJ, Morley EJ. The role of emergency department computed tomography in early acute pancreatitis. *Am J Emerg Med* 2021; **48**: 92-95 [PMID: 33866269 DOI: 10.1016/j.ajem.2021.04.026]

31 **Vacca G**, Reginelli A, Urraro F, Sangiovanni A, Bruno F, Di Cesare E, Cappabianca S, Vanzulli A. Magnetic resonance severity index assessed by T1-weighted imaging for acute pancreatitis: correlation with clinical outcomes and grading of the revised Atlanta classification-a narrative review. *Gland Surg* 2020; **9**: 2312-2320 [PMID: 33447582 DOI: 10.21037/gs-20-554]

32 **Stevens KJ**, Lisanti C. Pancreas Imaging. 2023 Mar 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan [PMID: 31613505]

33 **Stimac D**, Miletić D, Radić M, Krznarić I, Mazur-Grbac M, Perković D, Milić S, Golubović V. The role of nonenhanced magnetic resonance imaging in the early assessment of acute pancreatitis. *Am J Gastroenterol* 2007; **102**: 997-1004 [PMID: 17378903 DOI: 10.1111/j.1572-0241.2007.01164.x]

34 **O'Neill E**, Hammond N, Miller FH. MR imaging of the pancreas. *Radiol Clin North Am* 2014; **52**: 757-777 [PMID: 24889170 DOI: 10.1016/j.rcl.2014.02.006]

35 **Zhou Y**, Hao N, Duan Z, Kong M, Xu M, Zhang D, Xu X, Yuan Q, Li C. Assessment of Acute Pancreatitis Severity and Prognosis with CT-Measured Body Composition. *Int J Gen Med* 2021; **14**: 3971-3980 [PMID: 34349546 DOI: 10.2147/IJGM.S322589]

36 **Sun H**, Zuo HD, Lin Q, Yang DD, Zhou T, Tang MY, Wáng YXJ, Zhang XM. MR imaging for acute pancreatitis: the current status of clinical applications. *Ann Transl Med* 2019; **7**: 269 [PMID: 31355236 DOI: 10.21037/atm.2019.05.37]

37 **Williford ME**, Foster WL Jr, Halvorsen RA, Thompson WM. Pancreatic pseudocyst: comparative evaluation by sonography and computed tomography. *AJR Am J Roentgenol* 1983; **140**: 53-57 [PMID: 6600325 DOI: 10.2214/ajr.140.1.53]

38 **Türkvatan A**, Erden A, Türkoğlu MA, Seçil M, Yüce G. Imaging of acute pancreatitis and its complications. Part 2: complications of acute pancreatitis. *Diagn Interv Imaging* 2015; **96**: 161-169 [PMID: 24703377 DOI: 10.1016/j.diii.2013.12.018]

39 **Morgan DE**. Imaging of acute pancreatitis and its complications. *Clin Gastroenterol Hepatol* 2008; **6**: 1077-1085 [PMID: 18928934 DOI: 10.1016/j.cgh.2008.07.012]

40 **Ding L**, Yu C, Deng F, He WH, Xia L, Zhou M, Lan GL, Huang X, Lei YP, Zhou XJ, Zhu Y, Lu NH. New Risk Factors for Infected Pancreatic Necrosis Secondary to Severe Acute Pancreatitis: The Role of Initial Contrast-Enhanced Computed Tomography. *Dig Dis Sci* 2019; **64**: 553-560 [PMID: 30465178 DOI: 10.1007/s10620-018-5359-y]

41 **Balthazar EJ**, Freeny PC, vanSonnenberg E. Imaging and intervention in acute pancreatitis. *Radiology* 1994; **193**: 297-306 [PMID: 7972730 DOI: 10.1148/radiology.193.2.7972730]

42 **Balthazar EJ**, Robinson DL, Megibow AJ, Ranson JH. Acute pancreatitis: value of CT in establishing prognosis. *Radiology* 1990; **174**: 331-336 [PMID: 2296641 DOI: 10.1148/radiology.174.2.2296641]

43 **Mortele KJ**, Wiesner W, Intriere L, Shankar S, Zou KH, Kalantari BN, Perez A, vanSonnenberg E, Ros PR, Banks PA, Silverman SG. A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome. *AJR Am J Roentgenol* 2004; **183**: 1261-1265 [PMID: 15505289 DOI: 10.2214/ajr.183.5.1831261]

44 **Saneesh PS**, Garga UC, Gupta AK, Yelamanchi R. Role of multi-detector computed tomography in severity assessment of cases of acute pancreatitis. *Wien Klin Wochenschr* 2021; **133**: 654-660 [PMID: 33914151 DOI: 10.1007/s00508-021-01870-7]

45 **Mikó A**, Vigh É, Mátrai P, Soós A, Garami A, Balaskó M, Czakó L, Mosdósi B, Sarlós P, Erőss B, Tenk J, Rostás I, Hegyi P. Computed Tomography Severity Index vs. Other Indices in the Prediction of Severity and Mortality in Acute Pancreatitis: A Predictive Accuracy Meta-analysis. *Front Physiol* 2019; **10**: 1002 [PMID: 31507427 DOI: 10.3389/fphys.2019.01002]

46 **Song YS**, Park HS, Yu MH, Kim YJ, Jung SI. Prediction of Necrotizing Pancreatitis on Early CT Based on the Revised Atlanta Classification. *Taehan Yongsang Uihakhoe Chi* 2020; **81**: 1436-1447 [PMID: 36237716 DOI: 10.3348/jksr.2020.0012]

47 **Tasu JP**, Guen RL, Rhouma IB, Guerrab A, Beydoun N, Bergougnoux B, Ingrand P, Herpe G. Accuracy of a CT density threshold enhancement to identify pancreatic parenchyma necrosis in acute pancreatitis during the first week. *Diagn Interv Imaging* 2022; **103**: 266-272 [PMID: 34991994 DOI: 10.1016/j.diii.2021.12.003]

48 **Badat N**, Millet I, Corno L, Khaled W, Boulay-Coletta I, Zins M. Revised Atlanta classification for CT pancreatic and peripancreatic collections in the first month of acute pancreatitis: interobserver agreement. *Eur Radiol* 2019; **29**: 2302-2310 [PMID: 30631920 DOI: 10.1007/s00330-018-5906-0]

49 **Du J**, Zhang J, Zhang X, Jiang R, Fu Q, Yang G, Fan H, Tang M, Chen T, Li X, Zhang X. Computed tomography characteristics of acute pancreatitis based on different etiologies at different onset times: a retrospective cross-sectional study. *Quant Imaging Med Surg* 2022; **12**: 4448-4461 [PMID: 36060601 DOI: 10.21037/qims-21-1231]

50 **Bollen TL**, Singh VK, Maurer R, Repas K, van Es HW, Banks PA, Mortele KJ. Comparative evaluation of the modified CT severity index and CT severity index in assessing severity of acute pancreatitis. *AJR Am J Roentgenol* 2011; **197**: 386-392 [PMID: 21785084 DOI: 10.2214/AJR.09.4025]

51 **Sahu B**, Abbey P, Anand R, Kumar A, Tomer S, Malik E. Severity assessment of acute pancreatitis using CT severity index and modified CT severity index: Correlation with clinical outcomes and severity grading as per the Revised Atlanta Classification. *Indian J Radiol Imaging* 2017; **27**: 152-160 [PMID: 28744075 DOI: 10.4103/ijri.IJRI\_300\_16]

52 **Alberti P**, Pando E, Mata R, Vidal L, Roson N, Mast R, Armario D, Merino X, Dopazo C, Blanco L, Caralt M, Gomez C, Balsells J, Charco R. Evaluation of the modified computed tomography severity index (MCTSI) and computed tomography severity index (CTSI) in predicting severity and clinical outcomes in acute pancreatitis. *J Dig Dis* 2021; **22**: 41-48 [PMID: 33184988 DOI: 10.1111/1751-2980.12961]

53 **Liao Q**, He WH, Li TM, Lai C, Yu L, Xia LY, Luo Y, Zhu P, Liu H, Zeng Y, Zhu NH, Lyu N. Evaluation of severity and prognosis of acute pancreatitis by CT severity index and modified CT severity index. *Zhonghua Yi Xue Za Zhi* 2022; **102**: 2011-2017 [PMID: 35817726 DOI: 10.3760/cma.j.cn112137-20220424-00914]

54 **Dachs RJ**, Sullivan L, Shanmugathasan P. Does early ED CT scanning of afebrile patients with first episodes of acute pancreatitis ever change management? *Emerg Radiol* 2015; **22**: 239-243 [PMID: 25239388 DOI: 10.1007/s10140-014-1266-5]

55 **Working Group IAP/APA Acute Pancreatitis Guidelines**. IAP/APA evidence-based guidelines for the management of acute pancreatitis. *Pancreatology* 2013; **13**: e1-e15 [PMID: 24054878 DOI: 10.1016/j.pan.2013.07.063]

56 **Huang H**, Chen W, Tang G, Liang Z, Qin M, Qin M, Tang Y, Qin H, Chang R. Optimal timing of contrast-enhanced computed tomography in an evaluation of severe acute pancreatitis-associated complications. *Exp Ther Med* 2019; **18**: 1029-1038 [PMID: 31363364 DOI: 10.3892/etm.2019.7700]

57 **Pocard M**, Soyer P. CT of acute pancreatitis: a matter of time. *Diagn Interv Imaging* 2015; **96**: 129-131 [PMID: 25617113 DOI: 10.1016/j.diii.2015.01.001]

58 **Kumar P**, Gupta P, Rana S. Thoracic complications of pancreatitis. *JGH Open* 2019; **3**: 71-79 [PMID: 30834344 DOI: 10.1002/jgh3.12099]

59 **Song LJ**, Xiao B. Medical imaging for pancreatic diseases: Prediction of severe acute pancreatitis complicated with acute respiratory distress syndrome. *World J Gastroenterol* 2022; **28**: 6206-6212 [PMID: 36504558 DOI: 10.3748/wjg.v28.i44.6206]

60 **Liao YT**, Chiu NC, Chen CK, Su KC. Acute-on-chronic pancreatitis complicated with mediastinal pseudocysts and cardiac tamponade: A case report and literature review. *Respirol Case Rep* 2022; **10**: e0929 [PMID: 35309959 DOI: 10.1002/rcr2.929]

61 **Kozlov A**, Becher MU, Schlecker S. Hypertriglyceridemic pancreatitis and cardiac tamponade in a 26-year-old woman. *Inn Med (Heidelb)* 2023; **64**: 88-92 [PMID: 36418500 DOI: 10.1007/s00108-022-01434-5]

62 **Dąbkowski K**, Białek A, Kukla M, Wójcik J, Smereczyński A, Kołaczyk K, Grodzki T, Starzyńska T. Mediastinal Pancreatic Pseudocysts. *Clin Endosc* 2017; **50**: 76-80 [PMID: 27641151 DOI: 10.5946/ce.2016.089]

63 **Browne GW**, Pitchumoni CS. Pathophysiology of pulmonary complications of acute pancreatitis. *World J Gastroenterol* 2006; **12**: 7087-7096 [PMID: 17131469 DOI: 10.3748/wjg.v12.i44.7087]

64 **Luiken I**, Eisenmann S, Garbe J, Sternby H, Verdonk RC, Dimova A, Ignatavicius P, Ilzarbe L, Koiva P, Penttilä AK, Regnér S, Dober J, Wohlgemuth WA, Brill R, Michl P, Rosendahl J, Damm M. Pleuropulmonary pathologies in the early phase of acute pancreatitis correlate with disease severity. *PLoS ONE* 2022; **17**: e0263739 [PMID: 35130290 DOI: 10.1371/journal.pone.0263739]

65 **Peng R**, Zhang L, Zhang ZM, Wang ZQ, Liu GY, Zhang XM. Chest computed tomography semi-quantitative pleural effusion and pulmonary consolidation are early predictors of acute pancreatitis severity. *Quant Imaging Med Surg* 2020; **10**: 451-463 [PMID: 32190570 DOI: 10.21037/qims.2019.12.14]

66 **Raghu MG**, Wig JD, Kochhar R, Gupta D, Gupta R, Yadav TD, Agarwal R, Kudari AK, Doley RP, Javed A. Lung complications in acute pancreatitis. *JOP* 2007; **8**: 177-185 [PMID: 17356240]

67 **Yan G**, Li H, Bhetuwal A, McClure MA, Li Y, Yang G, Li Y, Zhao L, Fan X. Pleural effusion volume in patients with acute pancreatitis: a retrospective study from three acute pancreatitis centers. *Ann Med* 2021; **53**: 2003-2018 [PMID: 34727802 DOI: 10.1080/07853890.2021.1998594]

68 **Liu D**, Song B, Huang ZX, Yuan F, Li WM. The value of chest CT features evaluating the severity and prognosis for acute pancreatitis. *Sichuan Da Xue Xue Bao Yi Xue Ban* 2013; **44**: 319-322 [PMID: 23745281]

69 **Kothari S**, Kalinowski M, Kobeszko M, Almouradi T. Computed tomography scan imaging in diagnosing acute uncomplicated pancreatitis: Usefulness vs cost. *World J Gastroenterol* 2019; **25**: 1080-1087 [PMID: 30862996 DOI: 10.3748/wjg.v25.i9.1080]

70 **Bollen TL**, Singh VK, Maurer R, Repas K, van Es HW, Banks PA, Mortele KJ. A comparative evaluation of radiologic and clinical scoring systems in the early prediction of severity in acute pancreatitis. *Am J Gastroenterol* 2012; **107**: 612-619 [PMID: 22186977 DOI: 10.1038/ajg.2011.438]

71 **Shinagare AB**, Ip IK, Raja AS, Sahni VA, Banks P, Khorasani R. Use of CT and MRI in emergency department patients with acute pancreatitis. *Abdom Imaging* 2015; **40**: 272-277 [PMID: 25078061 DOI: 10.1007/s00261-014-0210-1]

72 **Kamal A**, Singh VK, Akshintala VS, Kawamoto S, Tsai S, Haider M, Fishman EK, Kamel IR, Zaheer A. CT and MRI assessment of symptomatic organized pancreatic fluid collections and pancreatic duct disruption: an interreader variability study using the revised Atlanta classification 2012. *Abdom Imaging* 2015; **40**: 1608-1616 [PMID: 25425489 DOI: 10.1007/s00261-014-0303-x]

73 **Bastati N**, Kristic A, Poetter-Lang S, Messner A, Herold A, Hodge JC, Schindl M, Ba-Ssalamah A. Imaging of inflammatory disease of the pancreas. *Br J Radiol* 2021; **94**: 20201214 [PMID: 34111970 DOI: 10.1259/bjr.20201214]

74 **Zhou T**, Tang MY, Deng Y, Wu JL, Sun H, Chen Y, Chen TW, Zhang XM. MR Imaging for Early Extrapancreatic Necrosis in Acute Pancreatitis. *Acad Radiol* 2021; **28** Suppl 1: S225-S233 [PMID: 31767534 DOI: 10.1016/j.acra.2019.10.023]

75 **Zhou T**, Chen Y, Wu JL, Deng Y, Zhang J, Sun H, Lan C, Zhang XM. Extrapancreatic Inflammation on Magnetic Resonance Imaging for the Early Prediction of Acute Pancreatitis Severity. *Pancreas* 2020; **49**: 46-52 [PMID: 31856079 DOI: 10.1097/MPA.0000000000001425]

76 **Jiang ZQ**, Xiao B, Zhang XM, Xu HB. Early-phase vascular involvement is associated with acute pancreatitis severity: a magnetic resonance imaging study. *Quant Imaging Med Surg* 2021; **11**: 1909-1920 [PMID: 33936974 DOI: 10.21037/qims-20-280]

77 **Xie CL**, Zhang M, Chen Y, Hu R, Tang MY, Chen TW, Xue HD, Jin ZY, Zhang XM. Spleen and splenic vascular involvement in acute pancreatitis: an MRI study. *Quant Imaging Med Surg* 2018; **8**: 291-300 [PMID: 29774182 DOI: 10.21037/qims.2018.03.04]

78 **Chi XX**, Zhang XM, Chen TW, Huang XH, Yang L, Tang W, Xiao B. The normal transverse mesocolon and involvement of the mesocolon in acute pancreatitis: an MRI study. *PLoS ONE* 2014; **9**: e93687 [PMID: 24705446 DOI: 10.1371/journal.pone.0093687]

79 **Chi XX**, Chen TW, Huang XH, Yang L, Tang W, Wáng YX, Xiao B, Zhang XM. Magnetic resonance imaging of retroperitoneal interfascial plane involvement in acute pancreatitis. *Quant Imaging Med Surg* 2016; **6**: 250-258 [PMID: 27429909 DOI: 10.21037/qims.2016.06.09]

80 **Ji YF**, Zhang XM, Mitchell DG, Li XH, Chen TW, Li Y, Bao ZG, Tang W, Xiao B, Huang XH, Yang L. Gastrointestinal tract involvement in acute pancreatitis: initial findings and follow-up by magnetic resonance imaging. *Quant Imaging Med Surg* 2017; **7**: 641-653 [PMID: 29312869 DOI: 10.21037/qims.2017.12.03]

81 **Xiao B**, Xu HB, Jiang ZQ, Zhang J, Zhang XM. Current concepts for the diagnosis of acute pancreatitis by multiparametric magnetic resonance imaging. *Quant Imaging Med Surg* 2019; **9**: 1973-1985 [PMID: 31929970 DOI: 10.21037/qims.2019.11.10]

82 **Tang MY**, Zhou T, Ma L, Huang XH, Sun H, Deng Y, Wang SY, Ji YF, Xiao B, Zhang XM. A new logistic regression model for early prediction of severity of acute pancreatitis using magnetic resonance imaging and Acute Physiology and Chronic Health Evaluation II scoring systems. *Quant Imaging Med Surg* 2022; **12**: 4424-4434 [PMID: 36060575 DOI: 10.21037/qims-22-158]

83 **Tang MY**, Chen TW, Bollen TL, Wang YX, Xue HD, Jin ZY, Huang XH, Xiao B, Li XH, Ji YF, Zhang XM. MR imaging of hemorrhage associated with acute pancreatitis. *Pancreatology* 2018; **18**: 363-369 [PMID: 29615311 DOI: 10.1016/j.pan.2018.03.004]

84 **Brun A**, Agarwal N, Pitchumoni CS. Fluid collections in and around the pancreas in acute pancreatitis. *J Clin Gastroenterol* 2011; **45**: 614-625 [PMID: 21750432 DOI: 10.1097/MCG.0b013e318213ef3e]

85 **Ahmed A**, Gibreel W, Sarr MG. Recognition and Importance of New Definitions of Peripancreatic Fluid Collections in Managing Patients with Acute Pancreatitis. *Dig Surg* 2016; **33**: 259-266 [PMID: 27216496 DOI: 10.1159/000445005]

86 **Lee DW**, Kim HG, Cho CM, Jung MK, Heo J, Cho KB, Kim SB, Kim KH, Kim TN, Han J, Kim H. Natural Course of Early Detected Acute Peripancreatic Fluid Collection in Moderately Severe or Severe Acute Pancreatitis. *Medicina (Kaunas)* 2022; **58**: 1131 [PMID: 36013598 DOI: 10.3390/medicina58081131]

87 **Lankisch PG**, Struckmann K, Lehnick D. Presence and extent of extrapancreatic fluid collections are indicators of severe acute pancreatitis. *Int J Pancreatol* 1999; **26**: 131-136 [PMID: 10732289 DOI: 10.1385/IJGC:26:3:131]

88 **Dhaka N**, Samanta J, Kochhar S, Kalra N, Appasani S, Manrai M, Kochhar R. Pancreatic fluid collections: What is the ideal imaging technique? *World J Gastroenterol* 2015; **21**: 13403-13410 [PMID: 26730150 DOI: 10.3748/wjg.v21.i48.13403]

89 **Sun H**, Jian S, Peng B, Hou J. Comparison of magnetic resonance imaging and computed tomography in the diagnosis of acute pancreatitis: a systematic review and meta-analysis of diagnostic test accuracy studies. *Ann Transl Med* 2022; **10**: 410 [PMID: 35530935 DOI: 10.21037/atm-22-812]

90 **Tang W**, Zhang XM, Xiao B, Zeng NL, Pan HS, Feng ZS, Xu XX. Magnetic resonance imaging versus Acute Physiology And Chronic Healthy Evaluation II score in predicting the severity of acute pancreatitis. *Eur J Radiol* 2011; **80**: 637-642 [PMID: 20843620 DOI: 10.1016/j.ejrad.2010.08.020]

91 **Xu N**, Li L, Zhao D, Wang Z, Wang X, Wang R, Zeng Y, Zhang L, Zhong N, Lv Y, Linghu E, Chai N. A preferable modality for the differentiation of peripancreatic fluid collections: Endoscopic ultrasound. *Endosc Ultrasound* 2022; **11**: 291-295 [PMID: 35083982 DOI: 10.4103/EUS-D-21-00130]

92 **Li J**, Zhang Q, Zhou A, Zhao G, Li P. Comparative outcomes of endoscopic ultrasound-guided lumen-apposing mental stents drainage for pancreatic pseudocysts and walled-off necrosis: Case series and meta-analysis. *Chronic Dis Transl Med* 2021; **7**: 157-168 [PMID: 34505016 DOI: 10.1016/j.cdtm.2021.07.001]

93 **Froes CD**, Gosal K, Singh P, Collier V. The Utility of Abdominal Ultrasound Following Negative Computed Tomography in Diagnosing Acute Pancreatitis. *Cureus* 2022; **14**: e27752 [PMID: 36106274 DOI: 10.7759/cureus.27752]

94 **Cai D**, Parajuly SS, Wang H, Wang X, Ling W, Song B, Li Y, Luo Y. Accuracy of contrast-enhanced ultrasound compared with conventional ultrasound in acute pancreatitis: Diagnosis and complication monitoring. *Exp Ther Med* 2016; **12**: 3189-3194 [PMID: 27882136 DOI: 10.3892/etm.2016.3760]

95 **Juneja D**. Ideal scoring system for acute pancreatitis: Quest for the Holy Grail. *World J Crit Care Med* 2022; **11**: 198-200 [PMID: 36331986 DOI: 10.5492/wjccm.v11.i3.198]

96 **Silva-Vaz P**, Abrantes AM, Castelo-Branco M, Gouveia A, Botelho MF, Tralhão JG. Multifactorial Scores and Biomarkers of Prognosis of Acute Pancreatitis: Applications to Research and Practice. *Int J Mol Sci* 2020; **21**: 338 [PMID: 31947993 DOI: 10.3390/ijms21010338]

97 **Ma X**, Li L, Jin T, Xia Q. Harmless acute pancreatitis score on admission can accurately predict mild acute pancreatitis. *Nan Fang Yi Ke Da Xue Xue Bao* 2020; **40**: 190-195 [PMID: 32376542 DOI: 10.12122/j.issn.1673-4254.2020.02.09]

98 **Ueda T**, Takeyama Y, Yasuda T, Kamei K, Satoi S, Sawa H, Shinzeki M, Ku Y, Kuroda Y, Ohyanagi H. Utility of the new Japanese severity score and indications for special therapies in acute pancreatitis. *J Gastroenterol* 2009; **44**: 453-459 [PMID: 19308309 DOI: 10.1007/s00535-009-0026-x]

99 **Lin F**, Lu R, Han D, Fan Y, Zhang Y, Pan P. A prediction model for acute respiratory distress syndrome among patients with severe acute pancreatitis: a retrospective analysis. *Ther Adv Respir Dis* 2022; **16**: 17534666221122592 [PMID: 36065909 DOI: 10.1177/17534666221122592]

100 **Wagner DP**, Draper EA. Acute physiology and chronic health evaluation (APACHE II) and Medicare reimbursement. *Health Care Financ Rev* 1984; **1984** (Suppl): 91-105 [PMID: 10311080]

101 **Wu Bu**, Johannes RS, Sun X, Tabak Y, Conwell DL, Banks PA. The early prediction of mortality in acute pancreatitis: a large population-based study. *Gut* 2008; **57**: 1698-1703 [PMID: 18519429 DOI: 10.1136/gut.2008.152702]

102 **Papachristou GI**, Muddana V, Yadav D, O'Connell M, Sanders MK, Slivka A, Whitcomb DC. Comparison of BISAP, Ranson's, APACHE-II, and CTSI scores in predicting organ failure, complications, and mortality in acute pancreatitis. *Am J Gastroenterol* 2010; **105**: 435-441 [PMID: 19861954 DOI: 10.1038/ajg.2009.622]

103 **Ranson JH**, Rifkind KM, Roses DF, Fink SD, Eng K, Localio SA. Objective early identification of severe acute pancreatitis. *Am J Gastroenterol* 1974; **61**: 443-451 [PMID: 4835417]

104 **Avanesov M**, Löser A, Smagarynska A, Keller S, Guerreiro H, Tahir E, Karul M, Adam G, Yamamura J. Clinico-radiological comparison and short-term prognosis of single acute pancreatitis and recurrent acute pancreatitis including pancreatic volumetry. *PLoS ONE* 2018; **13**: e0206062 [PMID: 30359398 DOI: 10.1371/journal.pone.0206062]

105 **Mounzer R**, Langmead CJ, Wu BU, Evans AC, Bishehsari F, Muddana V, Singh VK, Slivka A, Whitcomb DC, Yadav D, Banks PA, Papachristou GI. Comparison of existing clinical scoring systems to predict persistent organ failure in patients with acute pancreatitis. *Gastroenterology* 2012; **142**: 1476-1482 [PMID: 22425589 DOI: 10.1053/j.gastro.2012.03.005]

106 **Cho JH**, Kim TN, Chung HH, Kim KH. Comparison of scoring systems in predicting the severity of acute pancreatitis. *World J Gastroenterol* 2015; **21**: 2387-2394 [PMID: 25741146 DOI: 10.3748/wjg.v21.i8.2387]

107 **Yang L**, Liu J, Xing Y, Du L, Chen J, Liu X, Hao J. Comparison of BISAP, Ranson, MCTSI, and APACHE II in Predicting Severity and Prognoses of Hyperlipidemic Acute Pancreatitis in Chinese Patients. *Gastroenterol Res Pract* 2016; **2016**: 1834256 [PMID: 27882045 DOI: 10.1155/2016/1834256]

108 **Harshit Kumar A**, Singh Griwan M. A comparison of APACHE II, BISAP, Ranson's score and modified CTSI in predicting the severity of acute pancreatitis based on the 2012 revised Atlanta Classification. *Gastroenterol Rep (Oxf)* 2018; **6**: 127-131 [PMID: 29780601 DOI: 10.1093/gastro/gox029]

109 **Biberci Keskin E**, Taşlıdere B, Koçhan K, Gülen B, İnce AT, Şentürk H. Comparison of scoring systems used in acute pancreatitis for predicting major adverse events. *Gastroenterol Hepatol* 2020; **43**: 193-199 [PMID: 31924368 DOI: 10.1016/j.gastrohep.2019.10.008]

110 **Li Y**, Zhang J, Zou J. Evaluation of four scoring systems in prognostication of acute pancreatitis for elderly patients. *BMC Gastroenterol* 2020; **20**: 165 [PMID: 32487074 DOI: 10.1186/s12876-020-01318-8]

111 **Teng TZJ**, Tan JKT, Baey S, Gunasekaran SK, Junnarkar SP, Low JK, Huey CWT, Shelat VG. Sequential organ failure assessment score is superior to other prognostic indices in acute pancreatitis. *World J Crit Care Med* 2021; **10**: 355-368 [PMID: 34888161 DOI: 10.5492/wjccm.v10.i6.355]

112 **Venkatesh NR**, Vijayakumar C, Balasubramaniyan G, Chinnakkulam Kandhasamy S, Sundaramurthi S, G S S, Srinivasan K. Comparison of Different Scoring Systems in Predicting the Severity of Acute Pancreatitis: A Prospective Observational Study. *Cureus* 2020; **12**: e6943 [PMID: 32190494 DOI: 10.7759/cureus.6943]

113 **Asfuroğlu** **Kalkan E**, Kalkan Ç, Kaçar S, Barutçu S, Yüksel M, Güçbey Türker Ö, Göre B, Canlı T, Asfuroğlu U, Barutçu Asfuroğlu B, Hamamcı M, Kılıç V, Köseoğlu T, Özaslan E, Ödemiş B, Kılıç M, Yüksel İ, Ersoy O, Altıparmak E, Ateş İ, Soykan İ. Similarities and Differences Between Gerontal and Young Patients with Acute Pancreatitis: Evaluation of Clinical Characteristics and Outcomes. *Turk J Gastroenterol* 2022; **33**: 874-884 [PMID: 36205509 DOI: 10.5152/tjg.2022.22227]

114 **Singh VK**, Wu BU, Bollen TL, Repas K, Maurer R, Johannes RS, Mortele KJ, Conwell DL, Banks PA. A prospective evaluation of the bedside index for severity in acute pancreatitis score in assessing mortality and intermediate markers of severity in acute pancreatitis. *Am J Gastroenterol* 2009; **104**: 966-971 [PMID: 19293787 DOI: 10.1038/ajg.2009.28]

115 **Park JY**, Jeon TJ, Ha TH, Hwang JT, Sinn DH, Oh TH, Shin WC, Choi WC. Bedside index for severity in acute pancreatitis: comparison with other scoring systems in predicting severity and organ failure. *Hepatobiliary Pancreat Dis Int* 2013; **12**: 645-650 [PMID: 24322751 DOI: 10.1016/s1499-3872(13)60101-0]

116 **Chatterjee R**, Parab N, Sajjan B, Nagar VS. Comparison of Acute Physiology and Chronic Health Evaluation II, Modified Computed Tomography Severity Index, and Bedside Index for Severity in Acute Pancreatitis Score in Predicting the Severity of Acute Pancreatitis. *Indian J Crit Care Med* 2020; **24**: 99-103 [PMID: 32205940 DOI: 10.5005/jp-journals-10071-23343]

117 **Chandra S**, Murali A, Bansal R, Agarwal D, Holm A. The Bedside Index for Severity in Acute Pancreatitis: a systematic review of prospective studies to determine predictive performance. *J Community Hosp Intern Med Perspect* 2017; **7**: 208-213 [PMID: 29046745 DOI: 10.1080/20009666.2017.1361292]

118 **Valverde-López F**, Matas-Cobos AM, Alegría-Motte C, Jiménez-Rosales R, Úbeda-Muñoz M, Redondo-Cerezo E. BISAP, RANSON, lactate and others biomarkers in prediction of severe acute pancreatitis in a European cohort. *J Gastroenterol Hepatol* 2017; **32**: 1649-1656 [PMID: 28207167 DOI: 10.1111/jgh.13763]

119 **Chen L**, Lu G, Zhou Q, Zhan Q. Evaluation of the BISAP score in predicting severity and prognoses of acute pancreatitis in Chinese patients. *Int Surg* 2013; **98**: 6-12 [PMID: 23438270 DOI: 10.9738/0020-8868-98.1.6]

120 **Zhang J**, Shahbaz M, Fang R, Liang B, Gao C, Gao H, Ijaz M, Peng C, Wang B, Niu Z, Niu J. Comparison of the BISAP scores for predicting the severity of acute pancreatitis in Chinese patients according to the latest Atlanta classification. *J Hepatobiliary Pancreat Sci* 2014; **21**: 689-694 [PMID: 24850587 DOI: 10.1002/jhbp.118]

121 **Gao W**, Yang HX, Ma CE. The Value of BISAP Score for Predicting Mortality and Severity in Acute Pancreatitis: A Systematic Review and Meta-Analysis. *PLoS ONE* 2015; **10**: e0130412 [PMID: 26091293 DOI: 10.1371/journal.pone.0130412]

122 **Yadav J**, Yadav SK, Kumar S, Baxla RG, Sinha DK, Bodra P, Besra RC, Baski BM, Prakash O, Anand A. Predicting morbidity and mortality in acute pancreatitis in an Indian population: a comparative study of the BISAP score, Ranson's score and CT severity index. *Gastroenterol Rep (Oxf)* 2016; **4**: 216-220 [PMID: 25733696 DOI: 10.1093/gastro/gov009]

123 **Bezmarević M**, Kostić Z, Jovanović M, Micković S, Mirković D, Soldatović I, Trifunović B, Pejović J, Vujanić S. Procalcitonin and BISAP score versus C-reactive protein and APACHE II score in early assessment of severity and outcome of acute pancreatitis. *Vojnosanit Pregl* 2012; **69**: 425-431 [PMID: 22764546]

124 **Yang YX**, Li L. Evaluating the Ability of the Bedside Index for Severity of Acute Pancreatitis Score to Predict Severe Acute Pancreatitis: A Meta-Analysis. *Med Princ Pract* 2016; **25**: 137-142 [PMID: 26613249 DOI: 10.1159/000441003]

125 **Kim BG**, Noh MH, Ryu CH, Nam HS, Woo SM, Ryu SH, Jang JS, Lee JH, Choi SR, Park BH. A comparison of the BISAP score and serum procalcitonin for predicting the severity of acute pancreatitis. *Korean J Intern Med* 2013; **28**: 322-329 [PMID: 23682226 DOI: 10.3904/kjim.2013.28.3.322]

126 **Hagjer S**, Kumar N. Evaluation of the BISAP scoring system in prognostication of acute pancreatitis - A prospective observational study. *Int J Surg* 2018; **54**: 76-81 [PMID: 29684670 DOI: 10.1016/j.ijsu.2018.04.026]

127 **Zheng J**, Zhang J, Gao J. Early evaluations of BISAP plus C-reactive protein in predicting the severity of acute pancreatitis. *Zhonghua Yi Xue Za Zhi* 2015; **95**: 925-928 [PMID: 26081056]

128 **Wu B**, Yang J, Dai Y, Xiong L. Combination of the BISAP Score and miR-155 is Applied in Predicting the Severity of Acute Pancreatitis. *Int J Gen Med* 2022; **15**: 7467-7474 [PMID: 36187163 DOI: 10.2147/IJGM.S384068]

129 **Vincent JL**, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. *Intensive Care Med* 1996; **22**: 707-710 [PMID: 8844239 DOI: 10.1007/BF01709751]

130 **Kashyap R**, Sherani KM, Dutt T, Gnanapandithan K, Sagar M, Vallabhajosyula S, Vakil AP, Surani S. Current Utility of Sequential Organ Failure Assessment Score: A Literature Review and Future Directions. *Open Respir Med J* 2021; **15**: 1-6 [PMID: 34249175 DOI: 10.2174/1874306402115010001]

131 **Minne L**, Abu-Hanna A, de Jonge E. Evaluation of SOFA-based models for predicting mortality in the ICU: A systematic review. *Crit Care* 2008; **12**: R161 [PMID: 19091120 DOI: 10.1186/cc7160]

132 **Jentzer JC**, Bennett C, Wiley BM, Murphree DH, Keegan MT, Gajic O, Wright RS, Barsness GW. Predictive Value of the Sequential Organ Failure Assessment Score for Mortality in a Contemporary Cardiac Intensive Care Unit Population. *J Am Heart Assoc* 2018; **7**: e008169 [PMID: 29525785 DOI: 10.1161/JAHA.117.008169]

133 **Adam F**, Bor C, Uyar M, Demırağ K, Çankayalı İ. Severe acute pancreatitis admitted to intensive care unit: SOFA is superior to Ranson's criteria and APACHE II in determining prognosis. *Turk J Gastroenterol* 2013; **24**: 430-435 [PMID: 24557967 DOI: 10.4318/tjg.2013.0761]

134 **Tee YS**, Fang HY, Kuo IM, Lin YS, Huang SF, Yu MC. Serial evaluation of the SOFA score is reliable for predicting mortality in acute severe pancreatitis. *Medicine (Baltimore)* 2018; **97**: e9654 [PMID: 29443733 DOI: 10.1097/MD.0000000000009654]

135 **Para O**, Caruso L, Savo MT, Antonielli E, Blasi E, Capello F, Ciarambino T, Corbo L, Curto A, Giampieri M, Maddaluni L, Zaccagnini G, Nozzoli C. The challenge of prognostic markers in acute pancreatitis: internist's point of view. *J Genet Eng Biotechnol* 2021; **19**: 77 [PMID: 34036463 DOI: 10.1186/s43141-021-00178-3]

136 **Seymour CW**, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, Deutschman CS, Escobar GJ, Angus DC. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA* 2016; **315**: 762-774 [PMID: 26903335 DOI: 10.1001/jama.2016.0288]

137 **Qin X**, Lin H, Liu T, Zhao L, Li H. Evaluation value of the quick sequential organ failure assessment score on prognosis of intensive care unit adult patients with infection: a 17-year observation study from the real world. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2018; **30**: 544-548 [PMID: 30009728 DOI: 10.3760/cma.j.issn.2095-4352.2018.06.008]

138 **Rasch S**, Pichlmeier EM, Phillip V, Mayr U, Schmid RM, Huber W, Lahmer T. Prediction of Outcome in Acute Pancreatitis by the qSOFA and the New ERAP Score. *Dig Dis Sci* 2022; **67**: 1371-1378 [PMID: 33770328 DOI: 10.1007/s10620-021-06945-z]

139 **Wagner J**, Hernández Blanco YY, Yu A, Garcia-Rodriguez V, Mohajir W, Goodman C, DuPont AW, Cash BD, Farooq A. The Quick Sepsis-Related Organ Failure Assessment Score Is Prognostic of Pancreatitis Severity in Patients With Alcohol-Induced Pancreatitis. *Pancreas* 2022; **51**: 694-699 [PMID: 36206471 DOI: 10.1097/MPA.0000000000002095]

140 **Hallac A**, Puri N, Applebury D, Myers K, Dhumal P, Thatte A, Srikureja W. The Value of Quick Sepsis-Related Organ Failure Assessment Scores in Patients With Acute Pancreatitis Who Present to Emergency Departments: A Three-Year Cohort Study. *Gastroenterology Res* 2019; **12**: 67-71 [PMID: 31019615 DOI: 10.14740/gr1132]

141 **Lankisch PG**, Weber-Dany B, Hebel K, Maisonneuve P, Lowenfels AB. The harmless acute pancreatitis score: a clinical algorithm for rapid initial stratification of nonsevere disease. *Clin Gastroenterol Hepatol* 2009; **7**: 702-705 [PMID: 19245846 DOI: 10.1016/j.cgh.2009.02.020]

142 **Oskarsson V**, Mehrabi M, Orsini N, Hammarqvist F, Segersvärd R, Andrén-Sandberg A, Sadr Azodi O. Validation of the harmless acute pancreatitis score in predicting nonsevere course of acute pancreatitis. *Pancreatology* 2011; **11**: 464-468 [PMID: 21968430 DOI: 10.1159/000331502]

143 **Talukdar R**, Sharma M, Deka A, Teslima S, Dev Goswami A, Goswami A, Baro A, Nageshwar Reddy D. Utility of the "harmless acute pancreatitis score" in predicting a non-severe course of acute pancreatitis: a pilot study in an Indian cohort. *Indian J Gastroenterol* 2014; **33**: 316-321 [PMID: 24671724 DOI: 10.1007/s12664-014-0452-4]

144 **Maisonneuve P**, Lowenfels AB, Lankisch PG. The harmless acute pancreatitis score (HAPS) identifies non-severe patients: A systematic review and meta-analysis. *Pancreatology* 2021; **21**: 1419-1427 [PMID: 34629293 DOI: 10.1016/j.pan.2021.09.017]

145 **Gupta D**, Mandal NS, Arora JK, Soni RK. Comparative Evaluation of Harmless Acute Pancreatitis Score (HAPS) and Bedside Index of Severity in Acute Pancreatitis (BISAP) Scoring System in the Stratification of Prognosis in Acute Pancreatitis. *Cureus* 2022; **14**: e32540 [PMID: 36654581 DOI: 10.7759/cureus.32540]

146 **Al-Qahtani HH**, Alam MKh, Waheed M. Comparison of Harmless Acute Pancreatitis Score with Ranson's Score in Predicting the Severity of Acute Pancreatitis. *J Coll Physicians Surg Pak* 2017; **27**: 75-79 [PMID: 28292382]

147 **Hong W**, Lillemoe KD, Pan S, Zimmer V, Kontopantelis E, Stock S, Zippi M, Wang C, Zhou M. Development and validation of a risk prediction score for severe acute pancreatitis. *J Transl Med* 2019; **17**: 146 [PMID: 31068202 DOI: 10.1186/s12967-019-1903-6]

148 **He SS**, Li D, He QY, Chen XP, Lin YX, Yu YW, Chen FL, Ding J. Establishment of Early Multi-Indicator Prediction Models of Moderately Severe Acute Pancreatitis and Severe Acute Pancreatitis. *Gastroenterol Res Pract* 2022; **2022**: 5142473 [PMID: 35419053 DOI: 10.1155/2022/5142473]

149 **Feng A**, Ao X, Zhou N, Huang T, Li L, Zeng M, Lyu J. A Novel Risk-Prediction Scoring System for Sepsis among Patients with Acute Pancreatitis: A Retrospective Analysis of a Large Clinical Database. *Int J Clin Pract* 2022; **2022**: 5435656 [PMID: 35685488 DOI: 10.1155/2022/5435656]

150 **Tarján D**, Hegyi P. Acute Pancreatitis Severity Prediction: It Is Time to Use Artificial Intelligence. *J Clin Med* 2023; **12**: 290 [PMID: 36615090 DOI: 10.3390/jcm12010290]

151 **Qu C**, Gao L, Yu XQ, Wei M, Fang GQ, He J, Cao LX, Ke L, Tong ZH, Li WQ. Machine Learning Models of Acute Kidney Injury Prediction in Acute Pancreatitis Patients. *Gastroenterol Res Pract* 2020; **2020**: 3431290 [PMID: 33061958 DOI: 10.1155/2020/3431290]

152 **Yu X**, Wu R, Ji Y, Huang M, Feng Z. Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. *Diagnostics (Basel)* 2022; **12**: 3157 [PMID: 36553164 DOI: 10.3390/diagnostics12123157]

153 **Yue S**, Li S, Huang X, Liu J, Hou X, Zhao Y, Niu D, Wang Y, Tan W, Wu J. Machine learning for the prediction of acute kidney injury in patients with sepsis. *J Transl Med* 2022; **20**: 215 [PMID: 35562803 DOI: 10.1186/s12967-022-03364-0]

154 **Kui B**, Pintér J, Molontay R, Nagy M, Farkas N, Gede N, Vincze Á, Bajor J, Gódi S, Czimmer J, Szabó I, Illés A, Sarlós P, Hágendorn R, Pár G, Papp M, Vitális Z, Kovács G, Fehér E, Földi I, Izbéki F, Gajdán L, Fejes R, Németh BC, Török I, Farkas H, Mickevicius A, Sallinen V, Galeev S, Ramírez-Maldonado E, Párniczky A, Erőss B, Hegyi PJ, Márta K, Váncsa S, Sutton R, Szatmary P, Latawiec D, Halloran C, de-Madaria E, Pando E, Alberti P, Gómez-Jurado MJ, Tantau A, Szentesi A, Hegyi P; Hungarian Pancreatic Study Group. EASY-APP: An artificial intelligence model and application for early and easy prediction of severity in acute pancreatitis. *Clin Transl Med* 2022; **12**: e842 [PMID: 35653504 DOI: 10.1002/ctm2.842]

155 **Zhou Y**, Han F, Shi XL, Zhang JX, Li GY, Yuan CC, Lu GT, Hu LH, Pan JJ, Xiao WM, Yao GH. Prediction of the severity of acute pancreatitis using machine learning models. *Postgrad Med* 2022; **134**: 703-710 [PMID: 35801388 DOI: 10.1080/00325481.2022.2099193]

156 **Kiss S**, Pintér J, Molontay R, Nagy M, Farkas N, Sipos Z, Fehérvári P, Pecze L, Földi M, Vincze Á, Takács T, Czakó L, Izbéki F, Halász A, Boros E, Hamvas J, Varga M, Mickevicius A, Faluhelyi N, Farkas O, Váncsa S, Nagy R, Bunduc S, Hegyi PJ, Márta K, Borka K, Doros A, Hosszúfalusi N, Zubek L, Erőss B, Molnár Z, Párniczky A, Hegyi P, Szentesi A; Hungarian Pancreatic Study Group. Early prediction of acute necrotizing pancreatitis by artificial intelligence: a prospective cohort-analysis of 2387 cases. *Sci Rep* 2022; **12**: 7827 [PMID: 35552440 DOI: 10.1038/s41598-022-11517-w]

157 **Yuan L**, Ji M, Wang S, Wen X, Huang P, Shen L, Xu J. Machine learning model identifies aggressive acute pancreatitis within 48 h of admission: a large retrospective study. *BMC Med Inform Decis Mak* 2022; **22**: 312 [PMID: 36447180 DOI: 10.1186/s12911-022-02066-3]

158 **Hong W**, Lu Y, Zhou X, Jin S, Pan J, Lin Q, Yang S, Basharat Z, Zippi M, Goyal H. Usefulness of Random Forest Algorithm in Predicting Severe Acute Pancreatitis. *Front Cell Infect Microbiol* 2022; **12**: 893294 [PMID: 35755843 DOI: 10.3389/fcimb.2022.893294]

159 **Luo Z**, Shi J, Fang Y, Pei S, Lu Y, Zhang R, Ye X, Wang W, Li M, Li X, Zhang M, Xiang G, Pan Z, Zheng X. Development and evaluation of machine learning models and nomogram for the prediction of severe acute pancreatitis. *J Gastroenterol Hepatol* 2023; **38**: 468-475 [PMID: 36653317 DOI: 10.1111/jgh.16125]

160 **Yin M**, Zhang R, Zhou Z, Liu L, Gao J, Xu W, Yu C, Lin J, Liu X, Xu C, Zhu J. Automated Machine Learning for the Early Prediction of the Severity of Acute Pancreatitis in Hospitals. *Front Cell Infect Microbiol* 2022; **12**: 886935 [PMID: 35755847 DOI: 10.3389/fcimb.2022.886935]

161 **Zhang M**, Pang M. Early prediction of acute respiratory distress syndrome complicated by acute pancreatitis based on four machine learning models. *Clinics (Sao Paulo)* 2023; **78**: 100215 [PMID: 37196588 DOI: 10.1016/j.clinsp.2023.100215]

**Footnotes**

**Conflict-of-interest statement:** All the authors in this article declare there are no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 1, 2023

**First decision:** July 9, 2023

**Article in press:** September 14, 2023

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Akbulut S, Turkey; Kitamura K, Japan; Tsoulfas G, Greece **S-Editor:** Yan JP **L-Editor:** Filipodia **P-Editor:** Cai YX

**Table 1 Comparison of** **existing clinical** **scoring systems used in patients with acute pancreatitis for predicting the severity of** **acute pancreatitis, such as** **severe** **acute pancreatitis, mortality, organ failure, intensive care unit admission, location complications, in-hospital adverse events, and pancreatic necrosis**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Prediction** | **Scoring system (cutoff value)** | **Sensitivity, %** | **Specificity, %** | **Accuracy, %** | **PPV, %** | **NPV, %** | **AUC** | **No. of patients** | **Ref.** |
| MSAP and SAP1 | BISAP (≥ 3) | 54 | 86 | - | 68 | - | 0.795 | 326 | [107] |
| Ranson (≥ 3) | 46 | 84 | - | 54 | - | 0.766 |
| APACHE II (≥ 8) | 57 | 89 | - | 67 | - | 0.814 |
| MCTSI (≥ 4) | 36 | 94 | - | 66 | - | 0.654 |
| SAP1 | Ranson (≥ 3) | 85.7 | 44.3 | - | 18.8 | 95.3 | 0.69 | 161 | [106] |
| BISAP (≥ 2) | 61.9 | 72.1 | - | 25.0 | 92.7 | 0.74 |
| APACHE II (≥ 8) | 81.0 | 65.7 | - | 26.2 | 95.8 | 0.78 |
| CTSI (≥ 3) | 66.7 | 67.1 | - | 23.3 | 93.1 | 0.69 |
| SAP1,2 | Ranson (≥ 4/≥ 3) | 81.4/92.0 | 84.2/92.8 | - | 28.9/37.7 | 98.3/99.6 | 0.867/0.964 | 368/550 | [110] |
| BISAP (≥ 3/≥ 2) | 88.9/96.0 | 86.5/88.0 | - | 34.3/27.6 | 99.0/99.8 | 0.922/0.942 |
| APACHE II (≥ 9/≥ 8) | 85.2/96.0 | 61.0/93.0 | - | 14.7/42.9 | 98.1/99.8 | 0.784/0.951 |
| Glasgow (≥ 3/≥ 2) | 85.2/80.0 | 84.2/88.2 | - | 29.9/24.4 | 98.6/98.9 | 0.913/0.881 |
| SAP | HAPS (≥ 1) | 79.0 | 49.7 | 53.3 | 18.2 | 94.4 | 0.687 | 653 | [111] |
| BISAP (≥ 3) | 24.7 | 95.3 | 86.5 | 42.6 | 89.9 | - |
| APACHE II (≥ 8) | 80.2 | 63.3 | 65.4 | 23.6 | 95.8 | - |
| Ranson (≥ 3) | 92.6 | 51.9 | 57.0 | 21.4 | 98.0 | 0.857 |
| Glasgow (≥ 3) | 76.5 | 68.5 | 69.5 | 25.6 | 95.4 | - |
| SOFA (≥ 7) | 13.6 | 99.7 | 89.0 | 84.6 | 89.1 | 0.966 |
| SAP3 | APACHE II (≥ 6) | 50 | 100 | 68.3 | 100 | 53.57 | 0.771 | 164 | [112] |
| BISAP (≥ 2) | 25.96 | 100 | 53.1 | 100 | 43.80 | 0.640 |
| Modified Glasgow ≥ 3) | 75.96 | 100 | 84.8 | 100 | 70.59 | 0.649 |
| Ranson (≥ 2) | 32.69/58.65 | 100/100 | 57.3/73.8 | 100/100 | 46.15/58.25 | 0.848/0.817 |
| SAP3,4 | APACHE II (≥ 6) | 63.7 | 77.1 | 68.2 | 84.6 | 51.9 | - | 69 | [112] |
| BISAP (≥ 2) | 31.8 | 85.7 | 50.0 | 81.4 | 38.9 | - |
| Modified Glasgow (≥ 3) | 79.9 | 31.4 | 63.4 | 69.6 | 44.0 | - |
| Ranson (≥ 2) | 44.9/63.7 | 91.4/51.4 | 60.5/59.6 | 91.1/72.1 | 45.7/41.8 | - |
| Mortality1 | BISAP (≥ 3) | 89 | 80 | - | 15 | - | 0.867 | 326 | [107] |
| Ranson (≥ 3) | 78 | 77 | - | 9 | - | 0.842 |
| APACHE II (≥ 8) | 89 | 78 | - | 10 | - | 0.854 |
| MCTSI (≥ 4) | 78 | 86 | - | 14 | - | 0.839 |
| Mortality in AP | HAPS (≥ 1) | 83.3 | 46.6 | 29.9 | 2.8 | 99.3 | - | 653 | [111] |
| BISAP (≥ 3) | 25 | 93.1 | 91.9 | 6.4 | 98.5 | - |
| APACHE II (≥ 8) | 100 | 58.7 | 59.1 | 3.6 | 100 | - |
| Ranson (≥ 3) | 100 | 47.3 | 48.2 | 3.4 | 100 | 0.917 |
| Glasgow ≥ 3) | 75.0 | 63.8 | 64.2 | 4.1 | 99.5 | - |
| SOFA (≥ 7) | 50.0 | 98.9 | 98.0 | 46.2 | 99.1 | 0.968 |
| Mortality1 | BISAP (≥ 2.5) | 92.0 | 90.0 | - | - | - | 0.92 | 106 | [113] |
| HAPS (≥ 1.5) | 49.0 | 98.0 | - | - | - | 0.83 |
| Ranson (≥ 3.5) | 75.0 | 71.0 | - | - | - | 0.78 |
| JSS (≥ 3.5) | 84.0 | 94.0 | - | - | - | 0.92 |
| Glasgow (≥ 2.5) | 89.0 | 86.0 | - | - | - | 0.91 |
| APACHE II (≥ 5.5) | 90.0 | 92.0 | - | - | - | 0.94 |
| Persistent organ failure1,5 | APACHE II (≥ 7) | 84/94 | 71/44 | - | 49/14 | 93/99 | 0.77/0.71 | 256/397 | [105] |
| BISAP (≥ 2) | 61/62 | 84/76 | - | 54/20 | 87/96 | 0.72/0.69 |
| Glasgow (≥ 2) | 85/65 | 83/82 | - | 61/22 | 95/97 | 0.84/0.74 |
| HAPS (≥ 1) | 70/73 | 53/58 | - | 32/12 | 85/97 | 0.62/0.66 |
| JSS (≥ 2) | 59/42 | 92/89 | - | 70/23 | 88/95 | 0.76/0.66 |
| Ranson (≥ 2) | 66/46 | 78/80 | - | 49/16 | 88/95 | 0.72/0.63 |
| SIRS (≥ 2) | 70/69 | 71/58 | - | 43/11 | 88/96 | 0.70/0.64 |
| Organ failure1 | Ranson (≥ 3) | 88.89 | 96.67 | - | 88.89 | 96.67 | 0.757 | 50 | [108] |
| BISAP (≥ 3) | 90.00 | 83.87 | - | 64.29 | 96.30 | 0.762 |
| APACHE II (≥ 8) | 92.86 | 69.44 | - | 54.17 | 96.15 | 0.831 |
| MCTSI (> 4) | 92.86 | 75.00 | - | 59.09 | 96.43 | 0.893 |
| Association with organ failure3 | APACHE II (≥ 6) | 48.5 | 36.2 | 40.3 | 27.8 | 28.1 |  | 164 | [112] |
| BISAP (≥ 2) | 8.5 | 55 | 39.4 | 8.8 | 54.2 | 0.640 |
| Modified Glasgow (≥ 3) | 68.5 | 20.2 | 36.5 | 30.3 | 56 | 0.649 |
| Ranson (≥ 2) | 14.2/22.8 | 68.1/36.2 | 50/31.7 | 18.5/15.3 | 61/48 | 0.848/0.817 |
| ICU admission1 | Ranson (≥ 3) | 80.00 | 96.55 | - | 88.89 | 93.33 | 0.910 | 50 | [108] |
| BISAP (≥ 3) | 90.91 | 86.67 | - | 71.43 | 96.30 | 0.877 |
| APACHE II (≥ 8) | 92.31 | 65.71 | - | 50.00 | 95.83 | 0.885 |
| MCTSI (> 4) | 92.86 | 75.00 | - | 59.09 | 96.43 | 0.993 |
| ICU admission | HAPS ≥ 1 | 90.0 | 47.2 | 29.9 | 5.1 | 99.3 | - | 653 | [111] |
| BISAP ≥ 3 | 25.0 | 93.4 | 91.3 | 10.6 | 97.5 | - |
| APACHE II ≥ 8 | 100 | 59.6 | 60.5 | 6.6 | 100 | - |
| Ranson ≥ 3 | 100 | 47.9 | 49.5 | 5.7 | 100 | 0.946 |
| Glasgow ≥ 3 | 75.0 | 64.5 | 65.1 | 7.0 | 99.3 | - |
| SOFA ≥ 7 | 40.0 | 99.2 | 97.4 | 61.5 | 98.1 | 0.943 |
| Location complications1 | BISAP (≥ 3) | 54 | 81 | - | 21 | - | 0.731 | 326 | [107] |
| Ranson (≥ 3) | 57 | 79 | - | 20 | - | 0.698 |
| APACHE II (≥ 8) | 43 | 78 | - | 15 | - | 0.580 |
| MCTSI (≥ 4) | 68 | 90 | - | 38 | - | 0.791 |
| In-hospital adverse events1,6 | HAPS ≥ 2 | 66.2 | 70.6 |  | 36.0 | 89.1 | 0.70 | 690 | [109] |
| Ranson ≥ 3 | 66.9 | 62.8 | - | 31.2 | 88.3 | 0.68 |
| BISAP ≥ 2 | 61.9 | 75.9 | - | 39.3 | 88.7 | 0.74 |
| Glasgow ≥ 2 | 51.8 | 83.7 | - | 44.0 | 87.3 | 0.71 |
| JSS7 | 81.9 | 66.0 | - | 38.2 | 93.4 | 0.80 |
| Pancreatic necrosis1 | Ranson (≥ 3) | 80.00 | 96.55 | - | 88.89 | 93.33 | 0.910 | 50 | [108] |
| BISAP (≥ 3) | 81.82 | 83.33 | - | 64.29 | 92.59 | 0.822 |
| APACHE II (≥ 8) | 93.33 | 71.43 | - | 58.33 | 96.15 | 0.855 |
| MCTSI (> 4) | 93.33 | 77.14 | - | 63.64 | 96.43 | 0.993 |

1The predictive accuracy of each scoring system was measured by the area under the curve.

2In this study, 918 patients with were divided into two groups, namely the elderly group (368 patients who were ≥ 60-years-old) and the younger group (550 patients who were < 60-years-old). The former value corresponds to the elderly group, and the latter value corresponds to the younger group.

3The Ranson score in this study involved two time points: at admission and 48-h after admission. For Ranson, the former value corresponds to at admission, and the latter value corresponds to 48-h after admission.

4Computed tomography (CT) abdomen in 69 patients showed modified CT severity index ≥ 8 in all 69 (100%) patients.

5In this study, two prospective cohorts were involved, namely the training cohort and the validation cohort. The former value corresponds to the training cohort, and the latter value corresponds to the validation cohort.

6In-hospital adverse events included all in-hospital complications, pancreatic necrosis, and in-hospital mortality.

7Severe acute pancreatitis according to the Japanese Severity Score was defined if the prognostic factor was ≥ 3 or CT grade ≥ 2.

AP: Acute pancreatitis; APACHE: Acute Physiology and Chronic Health Evaluation; AUC: Area under the curve; BISAP: Bedside Index for Severity in Acute Pancreatitis; CTSI: Computed tomography severity index; HAPS: Harmless acute pancreatitis score; ICU: Intensive care unit; JSS: Japanese Severity Score; MCTSI: Modified Mortele’s computed tomography severity index; MSAP: Moderately severe acute pancreatitis; NPV: Negative predictive value; PPV: Positive predictive value; SAP: Severe acute pancreatitis; SIRS: Systemic Inflammatory Response Syndrome; SOFA: Sequential Organ Failure Assessment.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2023 Baishideng Publishing Group Inc. All rights reserved.**